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ABSTRACT
The maintenance of the hematopoietic stem and progenitor cell (HSPC)
population is critical to sustaining the adult blood and immune system throughout
an organism’s lifespan. The bone marrow microenvironment plays a key role in
the regulation of HSPC maintenance and functions. Previous work from our lab
has identified the tetraspanin CD82 as an important modulator of HSPC
interactions with the bone marrow niche. However, the mechanisms as to how
CD82 contributes to the maintenance, trafficking and retention of HSPCs with the
niche remained unclear. First, we investigated how CD82 promotes HSPC
quiescence, homing and engraftment using a global CD82 knock out (CD82KO)
mouse model. Our data demonstrate that CD82 promotes the maintenance of the
long-term HSC (LT-HSC) population within the bone marrow through increased
HSC quiescence. Additionally, we demonstrate that CD82KO HSPCs display
reduced bone marrow homing and engraftment, identifying a key role for CD82 in
these processes. We go on to demonstrate that Rac1 is hyperactivated in the
CD82KO HSPCs and inhibition directed to Rac1 restored HSPC homing and
migration.

While

HSPCs

primarily

reside

within

the

bone

marrow

microenvironment, they also traffic into the blood under steady state conditions
and upon treatment with mobilizing agents. We also identified CD82 as a novel
regulator of HSPC mobilization utilizing the CD82KO mouse model. Our data
demonstrate that CD82 promotes bone marrow retention, finding increased blood
mobilization in the CD82KO mice. Further studies identified the S1PR1 as a key
component of CD82-mediated mobilization. Additionally, intravenous treatment
with anti-CD82 antibodies resulted in enhanced HSPC mobilization in animal
models. Taken together, these data provide evidence that CD82 is a critical
regulator of HSPC quiescence, homing, engraftment and mobilization. More
importantly, these studies identify CD82 as a potential novel molecular target to
enhance HSPC transplantation therapies for the treatment of hematological and
non-hematological disorders.
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Chapter 1 – Introduction
1.1 Hematopoietic stem cells
1.1.1 History of hematopoietic stem cells
Research over the past 70 years has led to significant advances in the
field of hematopoietic stem cells (HSCs) resulting in improved treatments for
hematological malignancies. The need for hematopoietic research became
evident after residents of Hiroshima and Nagasaki were exposed to a continuous
low lethal dose of radiation due to the atomic bomb drop in 1945. This exposure
led to diseases that researchers now describe as hematopoietic failure.
Development of a treatment for hematological failure began in 1949, where
Jacobson et al. demonstrated mice exposed to a lethal dose of irradiation, where
lead plates shielded the spleen, resulted in increased survival (Jacobson et al.,
1949). This group later showed that mice were also protected when the femurs
were shielded with a lead plate (Jacobson et al., 1950). Additional studies found
that infusion of bone marrow or spleen cell suspensions into lethally irradiated
mice also increased survival (Lorenz et al., 1951). These studies suggested that
the spleen and bone marrow were critical organs for survival, but the population
of cells that were responsible for radioprotection remained unknown. Future,
transplantation studies provided evidence that the bone marrow and spleen
contained a specialized population of cells that possess self-renewal properties
(Barnes and Loutit, 1953; Main and Prehn, 1955). Work by other researchers
demonstrated that transplanted bone marrow could be detected within the
marrow of recipient mice, which further supported the fact that these specialized
cells were responsible for survival (Ford et al., 1956; Nowell et al., 1956).
However, it wasn’t until 1961 when Till and McCulloch demonstrated through
transplant studies that a single cell can have the capacity to self-renew and
differentiate into more than one type of blood and immune cell (Till and Mc,
1961). Ultimately, in 1963 Becker, Till and McCulloch, were able to determine
that this specialized group of cells with long-term self-renewing properties were
hematopoietic stem cells (HSCs) (Becker et al., 1963)
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1.1.2 Classification of hematopoietic stem and progenitor cells
Hematopoietic stem and progenitor cells (HSPCs) are a specialized
population of cells that have the capacity to self-renew and differentiate to
produce all blood and immune cells throughout an organism’s life. The HSPC
self-renewal and differentiation hierarchy is depicted in Figure 1.1. The hierarchy
of HSPC differentiation starts with a long-term hematopoietic stem cell (LT-HSC),
which has the capacity to self-renew or differentiate into a short-term
hematopoietic stem cell (ST-HSC), which then gives rise to multi-potent
progenitors (MPPs). MPPs differentiate into a common myeloid progenitor (CMP)
or common lymphoid progenitor (CLP), which ultimately give rise to terminally
differentiated blood and immune cells toward their restricted lineage type. Each
of these cell types will be further described below.

1.1.3 Long-term hematopoietic stem cells
LT-HSCs are the most primitive cells, which have the ability to self-renew
and repopulate the blood and immune system throughout an organism’s lifespan.
Currently, there is not a single surface marker that exclusively identifies LTHSCs. Rather, a combination of surface markers are used to isolate distinct
hematopoietic populations. The combination of surface markers used to identify
human hematopoietic stem cells is Lineage-CD34+CD38-CD90+CD45RA(Weissman and Shizuru, 2008). The first surface marker used to identify LTHSCs was CD34, which enriches for the HSC population, but still contains other
cell types such as lymphocyte progenitors (Civin et al., 1984; Strauss et al.,
1986). CD34 is a membrane glycoprotein, which is expressed on approximately
1-4% of bone marrow cells (Saeland et al., 1992). Early studies have shown that
CD34+ cells were able to establish hematopoiesis in lethally irradiated baboons
(Andrews et al., 1992). In combination with the CD34+ marker, CD90+ and
lineage negative (Lin-) markers further purify the LT-HSC population. Lineage
negative (Lin-) cells lack surface markers found on terminally differentiated blood
and immune cells. In addition, the surface marker CD90 is a GPI-linked
glycoprotein that is also expressed on human HSCs (Wisniewski et al., 2011). A
study showed that CD34+CD90+Lin- human cells harvested from different
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hematopoietic organs had long-term multi-lineage repopulating (LTMR) potential
in lethally irradiated SCID-hu mice (Whitlock et al., 1987).
Additional markers include the CD38 antigen which is expressed on >90%
of CD34+ cells, however, the CD34+CD38- population has been shown to have
multi-lineage

reconstitution

capabilities

after

transplantation

into

an

immunodeficient mouse (Bhatia et al., 1997). Moreover, another LT-HSC marker
is the surface glycoprotein CD45RA. CD45RA, which is an isoform of CD45,
identifies B cells, naïve T cells, common myeloid progenitor (CMP), granulocyte
myeloid progenitor (GMP) and myeloid erythroid progenitor (MEP) cells, however
has low surface expression on LT-HSCs (Galy et al., 1995; Manz et al., 2002).
One study demonstrated that the LT-HSCs identified by the markers, LineageCD34+CD38-CD90+CD45RA- had improved long-term engraftment potential
when compared to the CD90- population (Majeti et al., 2007). Collectively, these
studies provide evidence that human LT-HSCs can be identified by a
combination

of

the

following

surface

markers:

Lineage-CD34+CD38-

CD90+CD45RA-.
The hematopoietic differentiation lineages for a murine and human model
are identical, however, the markers used to identify each population of cells are
different. Initial irradiation studies where the bone marrow and spleen were
blocked by lead shields, ultimately demonstrating the hematopoietic system was
important for survival, were performed in mice. From this time, researchers
heavily used animal models (mostly mice) to further investigate the function of
hematopoietic stem cells. Therefore, the use of surface markers to identify
mouse LT-HSCs and ST-HSCs have been important for the advancement of
hematopoietic research. For the purpose of experiments explained in my
dissertation, the surface markers used to identify mouse LT-HSCs and ST-HSCs
are as follows: LT-HSCs are lineage-Sca1+ckit+CD34-CD135-CD48-CD150+,
whereas

ST-HSCs

are

lineage-Sca1+ckit+CD34+CD135-CD48-CD150+

(Weissman and Shizuru, 2008). Like human LT-HSCs, the mouse LT-HSC and
ST-HSC populations are also negative for lineage markers. However, mouse
HSPCs are commonly referred to as the “KLS” or “LSK” population, which is

3

negative for lineage and double positive for surface markers sca-1 and c-kit. To
further distinguish between the LT-HSC and ST-HSC populations, additive
markers are also used: CD34, CD135 and SLAM markers CD48 and CD150 (Kiel
et al., 2005; Yilmaz et al., 2006). In contrast to human LT-HSC markers, mouse
CD34 expression status is differentially expressed in which LT-HSCs are CD34and ST-HSCs are CD34+. While the combination of markers described is
commonly used to identify mouse LT- and ST-HSCs, researchers are constantly
trying to detect additional markers to further purify these cell populations.

1.1.4 Hematopoietic progenitor cells
Hematopoietic progenitor cells lack self-renewal properties but are
important for the differentiation of lineage restricted blood and immune cells. The
following surface markers are used to identify human hematopoietic progenitors:
Lineage-CD34+CD38-CD90-CD45RA- (Weissman and Shizuru, 2008). The
human progenitor markers are identical to the LT-HSC population, except CD90
is negatively expressed due to the lack of long-term multi-lineage repopulation
(LTMR) properties (Whitlock et al., 1987). Hematopoietic progenitor cell
populations still fall within the Lin- population due to the lack of surface
expression markers found on terminally differentiated blood and immune cells.
These progenitor cells can differentiate into two different lineages of blood and
immune cells that follow either a myeloid or lymphoid track (Weissman and
Shizuru,

2008).

The

megakaryocyte-erythroid

common

myeloid

progenitors

progenitor

(MEPs):

lineage

which

consists

differentiate

of
into

erythrocytes and platelets and granulocyte-macrophage progenitors (GMPs):
which differentiate into granulocytes, macrophages, and dendritic cells. The
common lymphoid progenitor lineage differentiates into dendritic cells, T cells, B
cells and natural killer cells. The overall differentiation of these blood and
immune cells is tightly regulated in order to maintain homeostatic conditions.
In mice, the following markers are used to identify multipotent progenitors
(MPP): Lineage-Sca1+ckit+CD34+CD135+CD48-CD150-. MPPs are part of the
LSK population, which also contains LT-HSCs and ST-HSCs. However, to further
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Figure 1.1: Diagram of hematopoiesis. Depicted is the hematopoietic stem and
progenitor (HSPC) cell self-renewal and differentiation hierarchy. The HSPC
population is collectively made up of the LT-HSCs, ST-HSCs and MPPs. The
hematopoietic progenitor population termed HPCs is similar to HSPCs but does
not consist of the LT-HSC and ST-HSC populations. Long-term HSCs have the
capacity to self-renew or differentiate into short-term HSCs, which then give rise
to multipotent progenitor cells. Multipotent progenitor cells then differentiate into
common myeloid or common lymphoid progenitors, which then have the capacity
to ultimately differentiate into blood and immune cells.

5

characterize the MPP population, SLAM markers are used. Downstream of
MPPs, progenitors differentiate into CMP or CLP lineages, which then give rise to
terminally differentiated cells based on their restricted lineage. Murine common
myeloid or lymphoid progenitors give rise to the same lineage restricted blood
and immune cells as human progenitors described in the section above.
Although the markers used to identify murine HSPCs are different from human
markers, the use of such surface markers for in vivo transplantation studies have
been critical to providing a better understanding for the function of HSPCs and
improving the efficacy of stem cell transplants for humans.
The expansion of HSPCs in vitro remains a major obstacle for
researchers. HSPCs can be cultured on feeder cells with a variety of
supplements but the quiescent properties are difficult to maintain. Currently, a
combination of the surface markers are used to identify each of these specialized
populations of HSPCs in culture through using positive and negative selection
antibodies and flow cytometry. Additionally, various colony forming unit (CFUs)
assays are used to identify different population of progenitors, where the
morphology and number of each colony identifies and quantifies progenitors that
are present within each population of HSPCs. However, the key functional
assays used to identify HSCs depend on in vivo studies using mice. Isolated
HSCs transplanted into lethally irradiated mice are used to measure the
repopulation capacity, in which long-term survival of a mouse indicates the
presence of a LT-HSC (Liu et al., 2012a). All it takes is one LT-HSC to engraft
into a lethally irradiated mouse in order for repopulation to occur (Abe et al.,
2010). Collectively, the identification of LT-HSCs through the use of surface
markers has proven to be important for the improvement of bone marrow
transplants.

1.1.5 Clinical use of hematopoietic stem cells
HSCs are commonly used in the clinic for treatment of a variety of
hematologic and non-hematologic malignancies such as leukemia, lymphoma
and neuroblastoma (Hatzimichael and Tuthill, 2010). Hematopoietic stem cell
transplants require intravenous administration of autologous, allogenic or
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syngeneic HSCs for re-establishment of the hematopoietic system of patients
undergoing myeloablative treatment (Copelan, 2006). These transplantation
methods each have benefits and weaknesses but the treatment regime heavily
depends on the patient’s age and disease. Autologous transplantation occurs by
transplanting HSCs from patient’s own bone marrow or blood to treat self.
Autologous HSCs are usually harvested when the patient is in remission or in a
state of low minimal residual disease. But, the risk of harvested HSCs containing
malignant cells still remains. One benefit of autologous transplants is bypassing
the likelihood of engrafted cells subsequently attacking the host tissues due to
contaminating T lymphocytes, known as graft-versus-host disease (Ferrara et al.,
1999). Although the patient is protected from graft-versus-host disease with
autologous transplantation, the benefit of allogenic transplantation is the graftversus-leukemia or graft-versus-tumor response. The graft-versus-leukemia or
graft-versus-tumor response is beneficial because transplanted cells are able to
recognize and attack malignant cells, which is important for achieving and
maintaining remission (Kolb, 2008; Porter, 2011). To get around this issue,
allogenic transplantation occurs by transplanting harvested HSCs from one
individual (not genetically identical) to treat another individual. For a successful
transplantation to occur, the patient and donor must have a close match between
6-10 major human leukocyte antigens (HLA) markers expressed on white blood
cells (Anasetti et al., 2001). An ideal donor would match all HLA markers of the
host because the more diverse the donor and host are, the higher the chance for
graft-versus-host disease. The third type of transplantation is syngeneic
transplantation, which occurs by transplanting HSCs from an identical twin (Fefer
et al., 1986). This type of transplantation is rare, but very similar to an autologous
transplant in which graft-versus-host disease does not occur in addition to graftversus-leukemia or graft-versus-tumor. The benefit of syngeneic transplantation
is the absence of donor malignant cells, which is a huge caveat of autologous
transplants. Additionally, the population of transplanted cells can be increased
since the donor is healthy and has not undergone any myeloablative treatment.
HSCs used for transplants are harvested from three different sources:
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bone marrow, peripheral blood and umbilical cord blood for transplantation
(Hatzimichael and Tuthill, 2010). Historically, bone marrow is the primary source
for collecting a large volume of HSCs. Bone marrow is collected using a
combination of large bore needles and heparinized syringes, which are
punctured into the posterior iliac crest or sternum. The ideal amount of
transplanted marrow is about 1-2x108/kg nucleated cells in order to establish
long-term engraftment (Bahceci et al., 2000). After collection, the marrow is
filtered to remove any debris or clots before intravenous injection into the
recipient. More recently, the use of peripheral blood stem cells (PBSCs) for
transplantations has become a favored option. Unlike bone marrow, PBSCs
harvest is significantly less laborious and invasive for the patient. A donor is
treated for about a week with a mobilizing drug, granulocyte colony-stimulating
factor (G-CSF) or AMD3100 to allow HSCs within the bone marrow to be
released into the peripheral blood (Bensinger et al., 1995; Schmitz et al., 1995).
However, due to low numbers/counts of circulating PBSCs, a donor must often
undergo a few rounds of apheresis to obtain enough cells. Apheresis is a
process by which circulating stem cells are removed and filtered from the blood
via a centrifugation-based machine. Evidence shows that infused PBSCs engraft
much quicker than bone marrow derived cells which could be due to higher
numbers of CD34+ cells and lymphoid progenitors (Korbling et al., 1995). The
third source of transplantable stem cells can be enriched from umbilical cord
blood. The advantage of cord blood transplant is the increased enrichment of
HSCs compared to other sources. Since cord blood tissue is relatively naïve, the
chances of GVHD by the resident immature immune cells are decreased, which
is beneficial for recipients who lack a suitable donor. Currently the major
problems with cord blood transplants are: poor engraftment, high non-relapse
mortality and poor survival (Rocha et al., 2009). In addition, other drawbacks
include limited amounts of tissue available and the high cost for this type of
transplant (Ballen, 2017).
At this time, HSCT is an active research area with continuous new
advances being made to improve the efficacy of harvest and transplantation
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methods. The use of HSCT for the treatment of hematological malignancies is
quite successful with only about 4% of patients dying within the first 100 days of
transplantation (Gribben et al., 2005). Although HSCs are commonly used to
treat various hematological disorders and solid tumors, two main issues remain:
1) HSCs are limited in number when harvested from a donor and 2) the likelihood
of HSCs effectively engrafting into the recipient bone marrow to restore
hematopoiesis is low. These issues are currently being researched in order to
identify key molecules and methods to improve the efficacy of HSC harvest and
transplants, which will ultimately improve the life of many individuals suffering
from non-hematological and hematological diseases.

1.2 Hematopoietic stem cell: self-renewal and differentiation
1.2.1 Asymmetric vs. symmetric divisions
Within the self-renewal and differentiation process, HSCs undergo
either asymmetric or symmetric cell division (Ho, 2005). Asymmetric cell division
occurs when a cell produces a daughter cell that retains intrinsic stem cell
properties and the other initiates differentiation (Caocci et al., 2017). This
process is critical for the maintenance of long-term hematopoiesis especially in
the event of a hematopoietic stem cell transplant to replenish the bone marrow
after myeloblative treatment. Both murine and human hematopoietic progenitor
cells were shown to undergo asymmetric divisions of about 20% from a single
progenitor cell (Leary et al., 1984; Leary et al., 1985). In an independent
approach, human cord blood HSCs were sorted and cultured into single cell
suspensions to determine the cell division fate. Under the described culture
conditions, asymmetric division was confirmed from a single cell in which
differentiation into another cell type was detected (Mayani et al., 1993). Using a
time-lapse camera system to monitor the replicative capacity of human HSCs,
one group demonstrated asymmetric divisions of CD34+ HSCs. They
demonstrated one daughter cell remained quiescent or divided very slowly while
the other multiplied quickly into progenitors and terminally differentiated cells
(Huang et al., 1999). HSCs are known to divide slowly, whereas differentiating
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cells undergo rapid proliferation. Interestingly, asymmetric division is more
frequent among CD34+CD38- cells, compared to CD34+CD38+ cells suggesting
that some populations have a greater replicative capacity (Huang et al., 1999).
The mechanism by which HSCs undergo self-renewal or differentiation
commitment is still unclear. Studies measuring the mitotic index and colony
formation of HSC division demonstrate that extracellular soluble molecules do
not influence asymmetric division. However, surface expression of CD53, CD63,
CD133, CD71, CD62L and CD34 was detected on HSCs that undergoing
asymmetric division (Beckmann et al., 2007; Giebel and Beckmann, 2007). The
expression of these surface proteins could influence the regulation of asymmetric
division in HSCs(Beckmann et al., 2007; Giebel and Beckmann, 2007).
Symmetric cell division occurs when a cell produces two daughter cells
that retain intrinsic stem cell or differentiation properties (Ho, 2005). This process
is important for HSC self-renewal in order to maintain homeostasis of the
primitive HSC pool. In the context of HSC transplantation, HSCs undergo
symmetric division in order to replenish the depleted malignant hematopoietic
system (Keller, 1992). The symmetric division of primitive HSCs is also important
to maintain the rare pool of HSCs that contain limitless self-renewal properties
(Ho, 2005).
HSC self-renewal in asymmetric and symmetric divisions is tightly
regulated through intrinsic and extrinsic signaling for the maintenance and
reconstitution of the stem cell pool. The self-renewal of HSCs is regulated by a
variety of signaling pathways such as Notch, Wnt, bone morphogenetic protein
(BMP), mTOR and Hedgehog (Bhardwaj et al., 2001; Butler et al., 2010;
Karlsson et al., 2007; Reya et al., 2003). The activation of these signaling
pathways results in the up-regulation of self-renewal genes such as β-Catenin,
SMAD and STAT3/5 (Zon, 2008), which is critical for the maintenance of the
HSC pool. The balance between asymmetric and symmetric division is important
for HSC pool maintenance. Nevertheless, over time and with increased age the
HSC pool becomes depleted due to aberrant activation of HSCs often leading to
downstream hematological pathologies (Rossi et al., 2005). HSC aging is defined
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by a decrease in HSC self-renewal, impaired bone marrow homing and
engraftment and skewing of myeloid lineage differentiation (Warren and Rossi,
2009). This decline is due to a decrease in red blood cell production and often
leads to an increase in myeloid cell differentiation (Rossi et al., 2008). Similar to
humans, HSCs from old mice display decreased bone marrow homing and
engraftment compared to HSCs from young mice (Morrison et al., 1996). The
decline in homing and engraftment in mice is due to an increase in cycling of the
old HSCs compared to the less active young HSCs. Another hallmark of HSC
aging is myeloid skewing, which is defined as an increase in myeloid production
and a decrease in lymphoid differentiation (Elias et al., 2017). A global gene
profile of LT-HSCs harvested from young and old mice determined that lymphoid
specific fate genes were down regulated and myeloid differentiation genes were
up regulated in aged mice (Rossi et al., 2008). Myeloid skewing is not only
influenced by intrinsic factors, but also extrinsic cues from the bone marrow
microenvironment. For example, one study demonstrated that HSC localization
within the bone marrow microenvironment can dictate lineage fate (Pinho et al.,
2018). This study demonstrated that HSCs in contact with megakaryocytes
resulted in myeloid bias, whereas, arteriole localization resulted in lymphoid bias.
Collectively, these studies provide evidence that HSC self-renewal and
differentiation processes are greatly influenced by age and a combination of
intrinsic and extrinsic factors.

1.3 Intrinsic regulation of hematopoietic stem cells
1.3.1 Introduction to intrinsic signals
HSCs are regulated by intrinsic signals that promote sustained selfrenewal and differentiation processes. Blood contains the highest turnover rate in
the body with the daily production of 1011-1012 new blood cells in a healthy
individual (Lampreia et al., 2017). Two signaling pathways that regulate HSC
self-renewal and differentiation are the Notch and Wnt/β-catenin signaling
pathways.
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1.3.2 Notch signaling
Notch is a highly conserved signaling pathway that functions to regulate
HSC self-renewal and fate determination (Bigas and Espinosa, 2012; Kopan and
Ilagan, 2009). Notch is heavily characterized for its role in T cell activation and
differentiation, however, its role in HSCs is less clear due to conflicting studies
(Bigas and Espinosa, 2012; Calvi et al., 2003; Karanu et al., 2000; Mancini et al.,
2005; Varnum-Finney et al., 2011). Notch is a transmembrane protein that is
activated through ligand-mediated interaction from cell-to-cell contact (Lampreia
et al., 2017). The receptor and ligand engagement results in two cleavage
processes mediated by first the metalloproteinase, TACE, and second by the γsecretase complex and APH1 to form the intracellular Notch receptor domain (NICD). The N-ICD domain translocates to the nucleus to bind to the DNA binding
protein, RBP-J, which ultimately induces gene expression changes in HSC
regulatory genes. Notch ligands and receptors have been identified in the bone
marrow and on HSPCs (Calvi et al., 2003; Duncan et al., 2005; Milner et al.,
1994). Studies have shown that a constitutively active form of Notch1 N-ICD
results in increased human HSPC self-renewal capacity (Carlesso et al., 1999).
In addition, in vitro exposure of primitive HSCs to Notch ligands promotes selfrenewal (Calvi et al., 2003; Karanu et al., 2000; Varnum-Finney et al., 2003). Itch
is an E3 ligase that negatively regulates Notch Signaling by inducing Notch
receptor degradation (Rathinam et al., 2011). In vivo studies show that mice
transplanted with Itch-deficient HSPCs resulted in expansion of the stem cell
pool. These data further suggest that Notch signaling plays a role in HSC
maintenance. In contrast, the deletion of the Notch ligand Jagged and Notch1
receptor in the bone marrow had no effect on hematopoietic pool (Mancini et al.,
2005). Similarly, the loss of either Notch 1 or Notch 2 had no effect on HSC
number in mice (Varnum-Finney et al., 2011). These conflicting results suggest
that Notch signaling may be important for HSC self-renewal and maintenance,
but other factors are likely to be involved and further studies are required.
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1.3.3 Wnt/β-catenin signaling
The Wnt/β-catenin signaling pathway is evolutionarily conserved and
important for HSC self-renewal and differentiation (Angers and Moon, 2009). Wnt
proteins are secreted glycoproteins that bind to the N-terminal domain of the Gprotein coupled receptor, Frizzled (Komiya and Habas, 2008). The Wnt signaling
pathway is activated upon Wnt binding to the Frizzled receptor complex with lowdensity lipoprotein co-receptors. Upon activation, the cytoplasmic phosphoprotein
Dishevelled forms a protein complex with GSK-3, Axin, APC and Ck1, which
results in the accumulation of β-catenin within the cytoplasm. β-catenin
undergoes nuclear translocation to the cytoplasm to bind the transcription factors
LEF/TCF and activate gene expression of target genes. Wnt signaling is
important for regulating the hematopoietic system during the fetal and adult
stages of development (Bigas et al., 2013; Lento et al., 2013). Both the ligand
and receptors of the Wnt/β-catenin pathway have been confirmed in the bone
marrow and on HSCs (Van Den Berg et al., 1998). Multiple studies have
demonstrated the importance of Wnt/β-catenin signaling in maintaining the HSC
stem cell pool. Mouse HSPCs transduced with constitutively active β-catenin
resulted in an increase in self-renewal and differentiation (Reya et al., 2003). In
addition, activation of β-catenin via GSK-3β inhibitors resulted in HSC expansion
(Trowbridge et al., 2006). Together, these studies provide evidence that the
Wnt/β-catenin pathway is critical for the maintenance and expansion of the HSC
pool.

1.4 Extrinsic regulation of hematopoietic stem cells
1.4.1 Bone marrow microenvironment
Extrinsic

regulation

of

HSCs

occurs

within

the

bone

marrow

microenvironment through a combination of cell-cell interactions from direct
contact or autocrine or paracrine signaling (Lin et al., 2015). Schofield
hypothesized in 1978 that stem cell behavior is determined by the types of cells it
interacts with (Schofield, 1978). HSCs primarily reside in the bone marrow, but
can also be found in other hematopoietic organs such as the blood, spleen, and
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Figure 1.2: Components of the hematopoietic stem cell niche. The bone
marrow microenvironment is also termed an endosteal niche. The main cellular
components of this niche consist of osteoblasts, osteoclasts and extracellular
matrix, which maintains the HSC population through extrinsic stimuli. In addition,
the vasculature niche, also known as the sinusoid, is made up of endothelial
cells. HSCs are able to migrate between the endosteal and vasculature niche by
extravasating through endothelial cells.
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liver. The bone marrow is a complex microenvironment that consists of different
cellular components to regulate HSC function and maintenance, including
osteoblasts, osteoclasts, stromal cells, mesenchymal stem cells (MSCs),
adipocytes and extracellular matrix (ECM) (Morrison and Scadden, 2014). The
different components of the bone marrow microenvironment are depicted in
Figure 1.2. Currently, it is believed that immature HSCs primarily reside within
the endosteal region, which is the inner surface of the long bone that is enriched
in mature osteoblasts (Balduino et al., 2005; Balduino et al., 2012; Nilsson et al.,
2005; Taichman et al., 2010). Early studies demonstrated that human CD34+
hematopoietic progenitor proliferation is stimulated by secretion of granulocyte
colony stimulating factor (G-CSF) by osteoblasts (Taichman et al., 2010). The
importance of osteoblasts for HSPC maintenance has been demonstrated
through a variety of in vivo studies. One key study using a transgenic mouse
engineered to increase osteoblast number demonstrated an increased
percentage of Lin-sca-1+c-kit+ (LSK) cells within the bone morrow compared to
control mice (Calvi et al., 2003). Additionally, another group showed that
increased spindle-shaped N-cadherin+CD45- osteoblasts (SNO) cells resulted in
increased numbers of long-term HSCs in vivo (Zhang et al., 2003), which further
supports a role for osteoblasts in HSC maintenance. Another study ablated bone
marrow osteoblasts, which resulted in a 3 to 10-fold decrease in HSPC number
due to reduced bone marrow cellularity (Visnjic et al., 2004). This reduction in
bone marrow cellularity resulted in an increase in extramedullary hematopoiesis
in the spleen. Conversely, osteoblastic activation increased bone marrow
cellularity, which reduced HSC activity and function (Schepers et al., 2012).
Collectively, these studies provide evidence that osteoblastic homeostasis within
the bone marrow is important for HSC bone marrow retention and activity.
Mesenchymal stem cells are multipotent stromal cells in the bone marrow
that provide additional HSC support (Smith and Calvi, 2013). Mesenchymal stem
cells are a heterogenous population of cells that can give rise to the osteogenic
lineage. These cells reside perivascularly but traffic to the endosteal surface of
the bone to differentiate into osteoblasts (Morrison and Scadden, 2014). One
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study confirmed increased localization of nestin GFP+ mesenchymal stem cells
around blood vessels throughout the bone marrow by immunostaining of mouse
femoral sections (Mendez-Ferrer et al., 2010). Mesenchymal stem cells were
also shown to be physically associated with HSCs using the same method
(Mendez-Ferrer et al., 2010). In addition, the co-transplantation of mesenchymal
stem cells with HSPCs increased bone marrow engraftment and enhanced selfrenewal (Ahn et al., 2010; Masuda et al., 2009). These data provide evidence
that mesenchymal stem cells are important regulators of HSC function.
In addition to the endosteal/osteoblastic niche, the vascular niche, shown
by the sinusoid in Figure 1.2 has been shown to play an equally important role in
HSC regulation. The bone marrow is highly vascularized and HSCs can be found
adjacent to the vasculature (Kiel et al., 2005). Endothelial cells function to
promote HSC maintenance within the bone marrow (Morrison and Scadden,
2014). Studies demonstrate that endothelial cells with nuclear β-catenin are
located adjacent to HSCs and are important for the emergence of HSCs (RuizHerguido et al., 2012). In addition, in vitro culture of endothelial cells with HSCs
promoted long-term reconstituting HSC expansion in culture (Cardier and
Barbera-Guillem, 1997; Ohneda et al., 1998). The ablation of endothelial cells
with the use of an anti-VE-cadherin antibody resulted in hematopoietic failure in
vivo (Avecilla et al., 2004). Collectively, these studies demonstrate the
importance of the vasculature for the maintenance of the HSC pool.
The extracellular matrix (ECM) within the bone marrow acts as a
supportive tissue for the maintenance of HSCs (Discher et al., 2009). ECM
creates a dynamic and complex environment that regulates HSC behavior.
Adhesion of HSCs to ECM inhibits proliferation and prevents apoptosis, which
results in long-term survival of quiescent HSCs (Krause, 2002). The bone
marrow microenvironment is thought to be comprised of collagen VI, collagenIV,
fibronectin, laminin and tenascin-C (Klein et al., 1993; Klein et al., 1995; Nilsson
et al., 1998). Integrins on the plasma membrane of HSCs are key receptors that
mediate ECM interactions within the bone marrow microenvironment. Integrins
are heterodimeric proteins that mediate HSC adhesion, migration and
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downstream signaling for HSCs (Legate et al., 2009). Evidence shows that
integrins inhibit cell proliferation through the activation of cell cycle inhibitors, p21
and p27 (Cheng et al., 2000a; Cheng et al., 2000b). Therefore, the adhesion of
HSCs to ECM via integrins is thought to be important for HSC quiescence.
Adipocytes have also been found to be important for HSC maintenance
within the bone marrow (Anthony and Link, 2014). Adipocyte number within the
bone marrow increases with age, which directly influences the number and
function of HSCs within the bone marrow (Naveiras et al., 2009). A study showed
that mice with adipocyte rich bone marrow had decreased HSC numbers
compared to controls with low adipose content (Naveiras et al., 2009)).
Therefore, these studies demonstrate that adipocytes can play an inhibitory role
in HSC activity. When taken together, the diverse components of the bone
marrow microenvironment are critical regulators of HSC maintenance and
function.

1.5 Hematopoietic stem cell quiescence
1.5.1 Introduction to hematopoietic stem cell quiescence
HSCs primarily reside within the bone marrow microenvironment in a
quiescent state. It is thought that quiescence or slowly cycling is necessary to
maintain primitive HSCs, in which a high cycling state is thought to be important
for the effective expansion of progenitor populations (Pietras et al., 2011). About
20-30% of the HSC population is within the quiescent phase of the cell cycle,
which means this population only cycles once every 150-200 days (Foudi et al.,
2009; Wilson et al., 2008). In contrast, more actively cycling hematopoietic
progenitor populations cycle once every 20-30 days (Foudi et al., 2009; Wilson et
al., 2008). In mice, about 90% of LT-HSCs remain within the G0 phase of the cell
cycle, with only 6% of this population entering into the active cycling phases each
day (Kiel et al., 2007a). HSC quiescence is not only important for protecting the
stem cell pool from mutations accumulated via active cycling, but also for
sustaining the HSC pool (Li, 2011). However, when quiescence is disrupted, the
HSC pool can undergo premature exhaustion, which can eventually lead to
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hematopoietic failure (Cheng et al., 2000b; Wilson and Trumpp, 2006). In the
event of an infection or blood loss, the demand of hematopoiesis increases,
which results in HSCs cycling out of a quiescent state from inflammatory cytokine
exposure (Baldridge et al., 2010; Essers et al., 2009; Morrison et al., 1997). HSC
quiescence in the bone marrow microenvironment is regulated by both extrinsic
and intrinsic mechanisms. The key players that initiate and regulate HSC
quiescence will be explained within this section.

1.5.2 Regulation of hematopoietic stem cell quiescence
The osteoblastic niche is critical for extrinsic regulation of HSCs through
the promotion of c-kit, Tie2/Ang-1, and TPO/MPL signaling (Li, 2011).
Osteoblasts secrete factors such as stem cell factor (SCF), angiopoietin (Ang-1)
and thrombopoietin (TPO) to mediate the interaction between HSCs and the
bone marrow microenvironment to promote HSC quiescence (Czechowicz et al.,
2007; Thoren et al., 2008). The disruption of the interaction between c-kit
receptor on HSCs and its ligand, stem cell factor (SCF) on osteoblasts resulted in
a decrease in HSC quiescence (Kiel et al., 2007a). In addition, Tie2/Ang-1
signaling mediates HSC quiescence through the activation of the PI3K/AKT
signaling pathway that results in increased gene expression of cell cycle inhibitor,
p21 (Visnjic et al., 2004). Moreover, TPO and and the myeloproliferative
leukemia virus proto-oncogene (MPL) signaling promotes HSC quiescence
through an increase in β1 integrin-mediated adhesion to osteoblasts (Yoshihara
et al., 2007). As before mentioned, HSC quiescence is promoted through integrin
mediated HSC adhesion to ECM by activating gene expression of cell cycle
inhibitors, p21 and p27 (Cheng et al., 2000a; Cheng et al., 2000b; Legate et al.,
2009) and mediated by the Wnt/ β-catenin and Notch signaling pathways
(Described in Section 1.3).
Molecules that mediate the interaction between osteoblasts and HSCs to
promote quiescence are N-cadherin and TGF-β (Haug et al., 2008; Li, 2011; Li
and Zon, 2010; Sitnicka et al., 1996). N-Cadherin and integrin β1 are both targets
of Tie2/Ang-1 and TPO/MPL signaling, promoting HSC quiescence (Li, 2011).
Overexpression of N-cadherin in HSPCs induced slow cell division, which
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protected the HSPCs from myelosuppression (Hosokawa et al., 2010a).
Conversely, the knock down of N-cadherin using shRNA resulted in reduced
bone marrow lodgment and adhesion of HSPCs in vivo, which significantly
reduced long term engraftment (Hosokawa et al., 2010b). These findings
prompted the authors to conclude that the inhibition of N-cadherin may affect the
ability of HSPCs to effectively adhere to the bone marrow microenvironment to
maintain quiescence However, the role of N-cadherin in regulating HSC function
still remains controversial; the basis being that deletion of N-cadherin in
osteoblasts does not affect HSC numbers or function, which suggests N-cadherin
is not important for the regulation of HSCs (Bromberg et al., 2012; Greenbaum et
al., 2012).
TGF-β is described as a potent inhibitor of HSC growth and critical
regulator of HSC quiescence (Sitnicka et al., 1996). TGF-β is thought to mediate
HSC quiescence through the increased expression of cell cycle inhibitors, p21
and p57 (Cheng et al., 2001; Dao et al., 1998), further illustrating the importance
of HSC quiescence and regulation of cell cycle-mediated transcription factors
and inhibitors. In addition, there are other transcription factors that mediate
HSPC quiescence such as, Gfi1, which is a zinc finger transcription repressor
that mediates HSC quiescence through the up regulation of p21 (Hock et al.,
2004; Zeng et al., 2004). In addition, the transcription factor pre-B cell acute
lymphoblastic leukemia (Pbx1) is preferentially expressed in LT-HSC population,
promoting quiescence via the TGF-β pathway (Ficara et al., 2008). Moreover, LTHSCs also express high levels of p53, which in combination with p21, results in
increased HSC quiescence (Dumble et al., 2007; Lacorazza et al., 2002). As
mentioned before, cell cycle inhibitors also play key roles in the regulation of cell
cycle maintenance of HSCs. The up-regulation of cell cycle inhibitors, such as
p21, p57 and p27, results in a decrease in cell-cycle activation, which promotes
HSC quiescence. The cell cycle inhibitor, p21 is a regulator of the G1 checkpoint.
The absence of p21 in mice led to increased HSC numbers due to enhanced
HSC proliferation (Zhang et al., 2003; Zhang et al., 1997). In addition, the loss of
p21 in mice also impaired HSC transplantation due to impaired self-renewal
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potential (Zhang et al., 2003). Futhermore, the cell cycle inhibitor p57 is also
important for regulation of cell cycle dynamics. TGF-β mediates the up regulation
of p57 expression, promoting cell cycle arrest within HSCs (Scandura et al.,
2004) Mouse studies demonstrated that p57 and p27 null HSCs had reduced
engraftment capacity and increased proliferation (Scandura et al., 2004; Zou et
al., 2011). Together, the transcription factors and cell cycle inhibitors described
are important for the regulation of HSC quiescence within the bone marrow
microenvironment.

1.6 Hematopoietic stem cell fitness
1.6.1 Introduction to hematopoietic stem cell fitness
Hematopoietic stem cell fitness is dictated by the combined ability of
HSCs to migrate, adhere and self-renew, differentiate and maintain quiescence
within the bone marrow microenvironment (Heazlewood et al., 2014). HSC
fitness is a multi-step process that requires a combination of adhesion and
signaling molecules to facilitate a successful engraftment for the restoration of
long-term hematopoiesis. HSC homing is the first step in this process, which is
regulated by the chemokine CXCR4/CXCL12 signaling axis. In addition, Rhorelated small GTPases such as Rac1 have been shown to play a role in
regulating HSPC adhesion, migration and homing (Chen et al., 2016; Gu et al.,
2003; Liu et al., 2011b; Yang et al., 2001). These homing molecules are
important for engraftment of HSCs within the bone marrow to establish
interactions with surrounding supportive cells. The interactions between HSCs
and the bone marrow microenvironment is necessary for the establishment of LTHSCs to repopulate blood and immune cells.

1.6.2 Hematopoietic stem cell homing
The active process by which HSCs migrate towards the bone marrow from
the vasculature is defined as homing. The homing process also occurs under
normal physiological conditions in which HSCs circulate at low levels within the
vasculature (Lapidot et al., 2005). HSC homing is a dynamic process that
involves complex communication of HSCs between chemokines, chemokine
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receptors, and adhesion molecules (Caocci et al., 2017).

The role of the

chemokine receptor CXCR4 and the corresponding ligand, CXCL12, in HSC
homing will be described more in depth in the next section labeled
“CXCR4/CXCL12 signaling”. In addition to chemokine signaling, adhesion
molecules such as integrin complexes (α4β1 (VLA-4) and α6β1) and selectins
(E-endothelial selectin and P-endothelial selectin) not only facilitate adhesion
within the bone marrow, but also mediate rolling and tethering of HSCs within the
blood vessels to enable trans-endothelial migration (Nabors et al., 2013). Other
molecules that mediate the interaction between HSCs and the endothelium to
facilitate homing are intercellular adhesion molecule-1 (ICAM-1) and vascular cell
adhesion molecule 1 (VCAM- 1) (Frenette et al., 1998; Mazo et al., 1998). In
combination, these molecules are critical for effective bone marrow homing which
ultimately results in successful HSC engraftment

1.6.2.1 CXCR4/CXCL12 signaling
The primary homing receptor for HSCs is the chemokine receptor,
CXCR4, which is a Gi-coupled protein receptor highly expressed on the surface
of HSCs. The ligand for CXCR4, CXCL12, is highly expressed and secreted by
stromal cells (expressed by osteoblasts and endothelial cells) within the bone
marrow microenvironment, thereby promoting chemotaxis of HSCs to the bone
marrow. Intracellular GTPases have been shown to promote HSC chemotaxis
through the activation of CXCR4 upon CXCL12 ligand binding (Marchese and
Benovic, 2001; Papayannopoulou et al., 2003). Downstream signaling of the
CXCR4 receptor leads to the activation of ERK, JAK/STAT and MAPK pathways
(Roland et al., 2003). The interaction between CXCR4-CXCL12 regulates not
only HSC homing, but also promotes HSC quiescence through the inhibition of
cell cycle progression, which is critical for HSC maintenance (Nie et al., 2008).
The importance of CXCL12 and CXCR4 for HSC homing was identified using a
combination of knock out mouse models and transplant studies. HSPCs isolated
from a CXCL12KO mouse showed a significant decrease in total bone marrow
engraftment in a competitive repopulation study (Tzeng et al., 2011). Whereas,
the loss of CXCR4 on HSPCs led to a significant decrease in bone marrow
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homing (Nie et al., 2008). Interestingly, bone marrow engraftment was rescued
with the re-expression of CXCR4, providing evidence that CXCL12/CXCR4
signaling axis is critical for HSC homing and bone marrow maintenance.

1.6.2.2 Rac 1 and hematopoietic stem and progenitor cells
Additional signaling stimulated downstream of CXCR4 includes the Rho
family of GTPases. GTPases act as molecular switches that cycle between a
GTP (active) and GDP (inactive) state. Upon activation through extracellular
signals, Rac1 converts from its active form via guanine nucleotide exchange
factors (GEFS) and to its inactive form via GTPase-activating proteins (GAPs)
(Bosco et al., 2009). Rac1 binding to the effector protein p21 activating kinase
(PAK) leads to the stimulation of downstream processes such as cytoskeletal
rearrangements, which further impacts cellular behaviors such as migration and
adhesion (Ridley, 2001).
Among the family of Rho GTPases, Rac1 is known to play a clear role in
HSPC migration and homing (Cancelas et al., 2005; Dorrance et al., 2013; Gu et
al., 2003; Liu et al., 2011b; Shang et al., 2011; Williams et al., 2008; Yang et al.,
2001). Rac1 has been shown to associate with CXCR4, in which inhibition of
Rac1 induces a conformational change of CXCR4 resulting in blocked receptor
internalization and impaired CXCL12 activation (Zoughlami et al., 2012). Using a
conditional Rac1KO mouse both resulted in impaired HSPC engraftment and
decreased adhesion to fibronectin (Gu et al., 2003). Interestingly, the deletion of
both Rac1 and Rac2 resulted in a significant increase in CXCR4 expression, but
migration to CXCL12 was decreased (Gu et al., 2003). These studies show the
importance of Rac1 for HSPC homing and engraftment using KO studies. The
dynamic process of HSPC circulation is also regulated by GTPase activity, which
mediates the tethering of HSPCs within the blood vessels to enable transendothelial migration (Mazo and von Andrian, 1999; Sahin and Buitenhuis,
2012). Rac1KO in HSCs resulted in a defect in long-term engraftment due to a
decrease in bone marrow homing (Cancelas et al., 2005). One study
demonstrated that endogenous Rac1 hyperactivation could decrease HSPC
bone marrow homing through the manipulation of R-Ras expression (Shang et
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al., 2011). The collective studies suggest Rac1 expression and activity are
important for the tight control of HSPC homing and engraftment.

1.6.3 Hematopoietic stem cell repopulation
HSC repopulation, also termed engraftment, is a critical step in
hematopoietic stem cell transplants. Similar to the HSC homing process, HSC
repopulation also requires a combination of signals from adhesion molecules to
mediate interactions between HSCs and the bone marrow microenvironment
(Mazo and von Andrian, 1999; Sahin and Buitenhuis, 2012). The cellular
components within the bone marrow microenvironment, such as osteoblasts and
endothelial cells, mediate the proper signals needed to promote engraftment and
downstream hematopoiesis (Anthony and Link, 2014). The expression of surface
markers can also influence engraftment potential of HSCs. HSCs that were
CD34+ had greater engraftment potential compared to CD34- HSCs when
transplanted in a lethally irradiated NOD/SCID mouse (Gao et al., 2001).
Molecular analysis comparing the expression of adhesion and homing genes
associated with HSPC homing showed an increase in VLA-4 and VLA-5 in the
Lin-CD34+ fraction compared to the Lin-CD34- fraction (Manfredini et al., 2005).
These data suggest that integrins on CD34+ cells have a role in increasing
engraftment potential compared to CD34- cells. However, additional adhesion
molecules used to identify primitive HSCs maybe involved with long-term
repopulation potential and would be beneficial to further increase engraftment.

1.6.4 Hematopoietic stem cell adhesion
The molecules that facilitate HSC maintenance within the bone marrow
and vasculature consist of adhesion molecules such as integrins, selectins and
cadherins. These adhesion molecules facilitate HSC homing and engraftment in
order to re-establish hematopoiesis. Integrin complexes, α4β1 (VLA-4) and αLβ2
(LFA-1) play an important role in HSC adhesion to the vasculature to aide in
trans-endothelial migration (Peled et al., 2000). Additionally, integrin complexes
α4β1 (VLA-4) and α6β1, are important for homing of HSCs to the bone marrow
and spleen (Papayannopoulou et al., 1995; Qian et al., 2006). Moreover,
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adhesion and chemotaxis of CD34+ HPCs on fibronectin were found to be
mediated by α5β1 (Carstanjen et al., 2005).
Selectins play an important role in rolling and tethering of HSCs within the
vasculature to mediate trans-endothelial migration. There are three different
selectins: P-selectin, E-selectin and L-selectin, in which only P- and E-selectin
have been shown to have a role in mediating HSC homing. In vitro studies,
demonstrated that CD34+ human cells rolling was induced on surfaces coated
with P- and E- selectins, but not L-selectin (Xia et al., 2004). In vivo
transplantation studies further confirmed that bone marrow engraftment of
HSPCs were dependent on P- and E- selectins (Frenette et al., 1998).
The cadherins, N-cadherin and VE-cadherin, are mediators of adhesion
within the vasculature and bone marrow compartment. Interestingly, the inhibition
of VE-cadherin on endothelial cells increase CD34+ HPC trans-endothelial
migration (van Buul et al., 2002). This suggests VE-cadherin also mediates
endothelial cell permeability to allow HPCs to traffic into the bone marrow. Ncadherin has been shown to mediate the interactions of HSCs with osteoblasts
within the bone marrow (Kiel et al., 2007b; Zhang et al., 2003). However, a few in
vivo studies show that deletion of N-cadherin in osteoblasts does not alter HSC
activity, therefore, the role of N-cadherin still remains controversial (Bromberg et
al., 2012; Greenbaum et al., 2012).

1.7 Hematopoietic stem cell mobilization
1.7.1 Introduction to hematopoietic stem cell mobilization
Mobilization is the active process HSCs undergo to migrate from the bone
marrow into the peripheral blood (Mohty and Ho, 2011). Under physiological
conditions, HSCs circulate at low levels within the vasculature to survey for
infection or injury (Massberg et al., 2007). The nervous system regulates
circadian mobilization, which results in oscillated release of HSCs throughout the
day (Mendez-Ferrer et al., 2009). It is well known that HSC bone marrow
retention and mobilization are mediated by CXCR4 and CXCL12. In addition, the
bioactive lipid receptor, sphingosphine-1-phosphate receptor (S1PR) promotes
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HSC trafficking in combination with CXCR4 signaling. Within the clinic, HSC
mobilization is often the chosen method used to isolate HSCs for transplants. For
a recent period (January 1, 2015 to Decemeber 31, 2016), The Seattle Cancer
Care Alliance at the Fred Hutchinson Cancer Research Center reported that the
majority of transplants were performed with stem cells taken from the peripheral
blood (https://bloodcell.transplant.hrsa.gov/). Mobilizing drugs such as AMD3100
and granulocyte-colony stimulating factor (G-CSF) are used individually or in
combination to mobilize HSCs into the peripheral blood, with G-CSF being the
most commonly used for transplantation.

1.7.2 Molecules that regulate hematopoietic stem cell mobilization
1.7.2.1 CXCR4/CXCL12 signaling
The interaction between CXCR4 expressed on HSCs and CXCL12
expressed in the bone marrow microenvironment promotes HSC retention.
CXCR4 expression on HSCs promotes quiescence within the bone marrow
critical for HSC maintenance (Nie et al., 2008). As previously described, the
CXCR4 receptor has also been shown be an important regulator of HSC homing
and engraftment. However, CXCR4 signaling has been shown to play an equally
important role in HSC mobilization (Nie et al., 2008; Tzeng et al., 2011). The
blockade of CXCR4 on HSCs with the use of clinically used drugs, AMD3100 and
G-CSF, promote mobilization. These mobilizing drugs target CXCR4 through
direct or indirect mechanisms in order to promote mobilization. These
mechanisms will be further discussed within this section.
CXCL12 is abundantly expressed on endothelial cells and osteoblasts
within the bone marrow microenvironment. However, disruption between the
interaction of CXCR4 and CXCL12 results in the release of HSCs into the
vasculature. CXCL12 expression is both intrinsically and extrinsically regulated
with the bone marrow. The Wnt signaling was shown to transcriptionally regulate
CXCL12 expression in bone marrow stromal cells (Tamura et al., 2011).
Extrinsically, G-CSF treatment leads to the proteolytic cleavage of the N-terminus
of CXCL12 and promotes the release of HSCs into the blood (Levesque et al.,
2003). CXCL12 levels are also regulated by proteases, which could also promote
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mobilization. Recent evidence shows that chronic variable stress can also
contribute to the down regulation of CXCL12, which results in HSC release (Heidt
et al., 2014). The pharmacological induction of HSC mobilization is used to
increase the release of HSCs in the blood for the use of hematopoietic stem cell
transplants.

1.7.2.2 Clinical drugs used to mobilize hematopoietic stem cells
1.7.2.2.1 Granulocyte colony stimulating factor (G-CSF)
G-CSF is important for the production of neutrophils and its effects are
mediated upon binding to a single homodimer of the G-CSF receptor (Fukunaga
et al., 1990). Under physiological conditions, G-CSF levels are undetectable,
however the levels increase upon infection. G-CSF was first used to treat
patients with neutropenia, which is a condition characterized by a decrease in
neutrophil production as a result of chemotherapy treatment (Bendall and
Bradstock, 2014). G-CSF treatment not only stimulated production of neutrophils,
but also induced mobilization of HSCs into the blood. The induction of HSC
mobilization by G-CSF treatment is an indirect response by HSCs. Studies have
shown that HSC release is due to the secretion of neutrophil associated
extracellular proteases such as matrix metalloproteinase 9 (MMP9), which led to
the degradation of bone marrow retention molecules (Petit et al., 2002). G-CSF
treatment also affects the bone marrow microenvironment by decreasing
osteoblast formation by blocking mesenchymal stem cell differentiation (Ferraro
et al., 2011; Semerad et al., 2005). Osteoblasts highly express CXCL12,
therefore the decrease in this bone marrow component results in HSC
mobilization. Today, G-CSF is routinely given to patients receiving chemotherapy
or those being treated to donate HSCs for transplantation. After administration of
G-CSF, the peak HSC mobilization occurs at 4-5 days (Uy et al., 2008). Although
G-CSF is highly effective in mobilizing HSCs, about 5-20% of patients fail to
mobilize a sufficient amount of cells (Mohty and Ho, 2011). Therefore, other
mobilizing drugs such as AMD3100 can be used to increase the efficacy of HSC
mobilization.
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1.7.2.2.2 AMD3100
AMD3100 (Plerixafor) was first discovered to have antiviral properties by
having

potential

inhibitory

effects

on

the

replication

of

the

human

immunodeficiency virus (HIV) (De Clercq et al., 1992). Soon after, AMD3100 was
found to be a selective antagonist for the chemokine receptor, CXCR4. Upon
AMD3100 treatment, the interaction between CXCR4 and CXCL12 is blocked,
inducing the mobilization of HSCs from the bone marrow into the blood. In
combination with G-CSF, AMD3100 treatment resulted in a dramatic increase in
the mobilization of CD34+ cells in comparison to just AMD3100 treatment alone
(Broxmeyer et al., 2005). In comparison to G-CSF where the peak HSC
mobilization occurs on a matter of 4-5 days, AMD3100 treatment occurs within
10-16 hours (Uy et al., 2008). AMD3100 and G-CSF treatment often requires
multiple sessions in order to obtain the necessary amount of HSCs for the use of
autologous and allogenic transplantations. In the context of autologous stem cell
transplants, one clinical study showed that combination treatment of AMD3100
and G-CSF resulted in increased stem cell mobilization, which required less
apheresis sessions (Uy et al., 2008). This situation would be ideal for patients
who often fail with G-CSF mediated mobilization alone.

1.7.2.3 Sphingosine 1-phosphate receptor 1 (S1PR1)
In addition to CXCR4, the S1PR is important for HSC trafficking and
mobilization. S1PR, like CXCR4, is classified as part of the G-protein-coupled-7transmembrane receptor family that modulate cell chemotaxis (Bendall and
Basnett, 2013). S1P receptors 1-5 all have unique roles in mediating cellular
processes that are not only restricted to hematopoietic stem cells (Blaho and Hla,
2014). S1PR1 is expressed on HSCs and is described as an important mediator
of HSC mobilization and trafficking (Golan et al., 2012; Juarez et al., 2012).
Combined treatment of AMD3100 and FTY720 (S1PR agonist), which binds and
targets the receptor for degradation, resulted in decreased numbers of mobilized
HSPCs compared to control treated animals (Golan et al., 2012). These data
demonstrate that S1PR1 plays an important role in HSPC mobilization. HSC
mobilization was enhanced by administration of the S1P analog, SEW2871
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(Juarez et al., 2012) and further increased used in combination with AMD3100.
This study demonstrates that high S1P levels in the vasculature sets up a
gradient for HSC mobilization that induces release from the osteoblastic niche
and trans-endothelial migration.
S1P is the ligand for the S1PR and is found at high concentrations within
the blood (Schwab et al., 2005). S1P levels within the blood are maintained by
endothelial cells (Ito et al., 2007; Liu et al., 2011a). The levels of S1P remain at
low concentrations within tissues and bone marrow in order to provide a
chemotactic gradient for HSC migration to the blood (Massberg et al., 2007).
Levels of S1P are regulated by the balance between type 1 sphingosine
phosphate-1 kinase (SphK1) and S1P lyase which degrades S1P levels (Pebay
et al., 2007). Interestingly, S1P is thought to be a stronger chemoattractant than
CXCL12/CXCR4-mediated

attraction

for

HSC

homing,

engraftment

and

mobilization (Golan et al., 2012; Juarez et al., 2012).

1.8 Tetraspanins and hematopoietic stem cells
1.8.1 Introduction to tetraspanins
The tetraspanin family of proteins function as scaffolds at the plasma
membrane to regulate a large array of cellular processes such as morphology,
migration, fusion and signaling (Hemler, 2003; Maecker et al., 1997; Wright et al.,
2004). The first members of tetraspanins were identified in human and
schistosomes (Hotta et al., 1988; Wright et al., 1990). There are 33 known
tetraspanins in humans, 37 in Drosophila and 20 in C. elegans (Adell et al., 2004;
Boucheix and Rubinstein, 2001; Todres et al., 2000). The expression of
tetraspanins across different species suggests this family of proteins contain an
evolutionary

conserved

structure

(Garcia-Espana

et

al.,

2008).

Some

tetraspanins such as CD9, CD81 and CD82 are ubiquitously expressed (Maecker
et al., 1997), whereas, other tetraspanins such as CD37 and CD53 are restricted
to hematopoietic cells (Maecker et al., 1997; Schwartz-Albiez et al., 1988). The
differential expression of tetraspanins in various tissues translates into specific
functions within different cell types.
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Tetraspanins protrude only 4-5 nm above the transmembrane, which often
results in them being overlooked by biochemical and immunological detection
(Hemler, 2005). A simplified schematic of the tetraspanin molecular structure is
depicted in Figure 1.3. Tetraspanins are characterized by four transmembrane
domains, which consist of two extracellular loops and two intracellular tails.
Tetraspanins range from 200-350 amino acids, in which 13-31 amino acids are in
the first extracellular loop (EC1 and 69-132 amino acids are in the second
extracellular loop (EC2) (Hemler, 2005; Stipp et al., 2003). EC2 contains a region
with three alpha helices and a variable region, which is important for tetraspanin
protein-protein interactions (Hemler, 2003; Stipp et al., 2003). EC2 also contains
a conserved CCG motif and two cysteines that also consist of two di-sulfide
bonds (Hemler, 2003; Stipp et al., 2003). Proteins are only characterized as a
tetraspanin if they contain 4-6 conserved extracellular cysteines residues and
polar residues within the trasnsmembrane domains (Hemler, 2005; Stipp et al.,
2003).

A new crystal structure of full length CD81 provided evidence that

tetraspanins also consist of a cholesterol-binding pocket created by the four
transmembrane domain structure (Zimmerman et al., 2016). This structure also
provided evidence that tetraspanin function can be mediated by an open or
closed conformation due to the binding of cholesterol at the binding pocket. For
example, cholesterol binding regulates CD81 function by mediating the export of
CD19 to the surface of 293T cells (Zimmerman et al., 2016), however, it is still
unknown how cholesterol binding affects the function of other tetraspanins.
Tetraspanins contain post-translational modifications that mediate the
unique function of each transmembrane protein. The post-translational
modification sites on tetraspanins include palmitylotation, N-glycosylation, and
ubiquitination. Additionally, tetraspanins have a cytoplasmic tail-sorting motif
YXXΦ. The addition of palmitate to the membrane proximal cysteine residues
facilitates the stability of the tetraspanin within the membrane (Levy and Shoham,
2005). Tetraspanins CD9, CD37, CD53, CD63, CD81, CD82 and CD151 were
found to incorporate palmitate (Charrin et al., 2002). Tetraspanin palmitylotation
promotes formation of tetraspanin enriched mirco-domains (TEMs), which
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Figure 1.3: Diagram of tetraspanin molecular structure. This diagram is
based off the crystal structure of CD81 published in, (Zimmerman et al., 2016).
The molecular structure of tetraspanins depicts four transmembrane domains
(TM1-TM4). These transmembrane domains create three loops, one small
extracellular (EC1), one large extracellular loop (EC2) and one small intracellular
loop. Tetraspanins also consist of two intracellular tails, N-termini and C-termini.
The Cys-Cys-Gly amino acid motif and two disulfide bonds are located on EC2.
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contributes to tetraspanin-dependent signaling (Charrin et al., 2002). Loss of
palmitoylation results in decreased lateral associations of CD151 and CD9
(Berditchevski et al., 2002; Charrin et al., 2002; Yang et al., 2002). Palmityolation
mutants of CD82 led to the disorganization of CD82 clusters at the plasma
membrane of AML cells (Termini et al., 2014). In addition, palmityolation was
also found to be important for the tight packing of the α4 integrin at the plasma
membrane.

Moreover, tyrosine phosphorylation of the nucleotide exchange

factor, Vav1, has been shown to be dependent on the interaction between
palmityolated tetraspanins and cholesterol (Charrin et al., 2003). Most
tetraspanins are heavily glycosylated, which contributes to the heterogeneity in
size of 20 to 50kDa (Yunta and Lazo, 2003). N-glycosylation sites are expressed
on the first and second extracellular loop of tetrspanins and are important for cellcell interactions and the organization of the structure (Stipp et al., 2003). Studies
from our lab and others show the importance of N-linked glycosylation sites for
tetraspanin functions. Our lab demonstrated that the loss of CD82 Nglycosylation sites led to increased clustering of N-cadherin on the plasma
membrane resulting in increased bone marrow homing of AML cells (Marjon et
al., 2016). In addition, another group showed that N-glycosylation of CD82
regulated adhesion and motility through the interaction with α3 and α5 (Ono et
al., 2000). In addition, N-glycosylation sites on CD63 mediated the down
regulation of CXCR4 (Yoshida et al., 2009).
The YXXΦ cytoplasmic tail-sorting motif consists of a Tyr-Xaa-Xaa-Φ motif
in which the Φ represents a bulky hydrophobic side chain amino acid (Bonifacino
and Dell'Angelica, 1999). The YXXΦ sorting motif found on the C-terminal tail of
specific tetraspanins is important for endocytosis (Rous et al., 2002). For
example this motif has been found to be important for internalization of CD151,
Tspan7 and CD82 (Liu et al., 2007; Rous et al., 2002; Stipp et al., 2003). The Cterminal tail motif is also important for endocytic trafficking, localization and
lysosomal targeting (Bonifacino and Dell'Angelica, 1999). Mutations in the sorting
motif of CD63 resulted in the lost of intracellular localization and cell surface
trafficking (Rous et al., 2002). Tetraspanins without this sorting motif can also be
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Table 1.1: Tetraspanin regulation of hematopoietic stem and progenitor cell
function. Tetraspanins have been shown to play a role in regulating
hematopoietic stem and progenitor cell functions. This table lists the roles of
each tetraspanin in respect to HSPC function.
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localized to intracellular compartments such as endosomes, late endosomes and
lysosomes by interacting with tetraspanins with this sort motif (Stipp et al., 2003).
Tetraspanin enriched micro-domains (TEMs) function as a membrane
scaffold that regulates adhesion and signaling. Tetraspanins can interact with
other tetraspanins, adhesion molecules, signaling molecules and Ig receptors to
form TEMs (Serru et al., 1999; Szollosi et al., 1996; Termini et al., 2014). With
the

use

of

biochemical

techniques

and

super

resolution

microscopy,

tetrasapanins have been shown to influence integrin clustering and avidity
(Thoren et al., 2008). In addition, tetraspanins are known to interact with
signaling molecules at the membrane in order to elicit down stream signaling. For
example, Rac1 activation is mediated by CD81 expression through the
interaction with the C-terminal tail (Tejera et al., 2013). In addition, PKCα has
also been shown to interact with the intracellular tails of tetraspanins upon PMA
stimulus to promote down stream signaling (Zhang et al., 2001). In addition,
CD82-associated TEMs stabilize PKCα activation at the plasma membrane to
promote down stream ERK signaling (Termini et al., 2016). Therefore,
tetraspanins acts as molecular facilitators that coordinate and organize the
membrane to promote down stream signaling to activate cell-mediated behaviors
(Termini and Gillette, 2017). The following section will describe how tetraspanins
specifically regulate HSC functions and behaviors, which are summarized in
Table 1.1.

1.8.2 Tetraspanins as regulators of hematopoietic stem cell function
1.8.2.1 CD9
Tetraspanin CD9 expression has been described on hematopoietic stem
and progenitor cells (HSPCs) where it was shown to regulate HSPC proliferation,
migration and adhesion. The use of surface markers is critical for the
identification of a pure population of HSPCs. CD9 expression was used as
marker to enrich HPCs in a porcine model (Heinz et al., 2002). This study
identified seven markers for negative enrichment of hematopoietic progenitor
cells (HPCs), one of which was CD9. Here, HPCs with negative or low
expression of CD9 fell within the side population, which is a technique used to
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identify putative HSCs. In contrast, CD9 has also been identified as a positive
marker for HSCs and HSPCs in the following systems: murine HSCs (Karlsson et
al., 2013), bone marrow derived multipotent hematopoietic progenitor cell line
(Bruno et al., 2004) and human umbilical cord blood stem cells (Zhao et al.,
2006).
In addition to being used as a surface marker for HSPCs, CD9 has also
been shown to regulate HSPC migration, adhesion and homing (Leung et al.,
2011). This study showed that CD9 expression on human cord blood CD34+
HSPCs was modulated by SDF-1 and CXCR4 activity to increase HSPC
migration and adhesion. Additionally, this group demonstrated that enhancing
CD9 expression on the surface of CD34+ HSPCs with the treatment of a protein
kinase C agonist, ε ingenol 3,20 dibenzoate (IDB), increases homing to the bone
marrow. However, another group later found that IDB increases CD9 expression
on CD34+ HSPCs, but does not increase HSPC homing compared to control
treated CD34+ HSPCs intravenously injected into NSG mice (Desmond et al.,
2011). More recently, another group characterized human CD34- HSCs isolated
from cord blood and found that engraftment in mice and sheep was limited due to
a decrease in CD9 and an increase in the inhibitory homing molecule, CD26
(Abe et al., 2017). Together these data suggest that CD9 can be used as a
marker for HSPCs and has a role in HSPC adhesion and migration.
CD9 is also expressed on the surface of dendritic cells derived from
CD34+ HPCs isolated from human cord blood (Caux et al., 1996). Human
CD34+ HPCs cultured in vitro in the presence of the hematopoietic growth factor,
granulocytic-macrophage-colony stimulating factor (GM-CSF) and tumor necrosis
factor-alpha (TNF-alpha) differentiated along two independent dendritic cell
pathways: 1) CD1a+ dendritic cells and 2) CD14+ dendritic cells. Day 12 of
culture yielded CD14+ progenitors that differentiated into dendritic cells
characterized by the expression of CD9, CD68, CD2 and factor XIIIa. Functional
assays showed that CD14+ dendritic cells are unique from CD1a dendritic cells,
which could be important in immune responses (Caux et al., 1997). Therefore,
these studies suggest that CD9 is important for immune cell differentiation.
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Finally, the expression of CD9 on stromal cells also regulates HSPC
activity (Aoyama et al., 1999; Oritani et al., 2000). The pluripotent hematopoietic
cell line, EML-C1, plated on stromal cells ligated with an anti-CD9 antibody
blocked HSC differentiation, proliferation and self-renewal. The authour
speculated that the interaction of CD9 with integrin β1 and an unknown 100kD
protein leads to the inhibition of HSPC differentiation. The identification of this
unknown 100kD protein could be important in determining a novel regulator for
HSPC activity.

1.8.2.2 CD81
HSCs primarily reside in a quiescent state within the bone marrow
microenvironment. The tetraspanin CD81 was shown to be important for the reentry of HSC quiescence through the inhibition of the Akt signaling pathway (Lin
et al., 2011). This group found that the spatial distribution of CD81 on the surface
of murine HSCs was important for the re-entry of HSCs into quiescence from a
highly proliferative state. The polarization of CD81 leads to the deactivation of
Akt and nuclear translocation of FoxO1a, which resulted in an increase in
quiescence. Therefore, CD81 is important for the regulation of HSC quiescence.
The tetraspanin CD81 has been shown to serve as a marker for the
development of lymphohematopoietic stem and progenitor cells (Ma et al., 2001).
Differential surface expression of CD81 and CD34 caused differentiation of
CD34+ HSPCs into specific lineages of blood and immune cells. Therefore,
CD81 expression can be useful for determining the differentiation status of
lymphohematopoietic stem and progenitor cells
Finally, within tetraspanin-enriched micro-domains (TEMs), CD81 has
been shown to interact with integrins and the c-kit receptor tyrosine kinase in
human hematopoietic progenitors (Anzai et al., 2002). Using a combination of
immunoprecipitation and co-localization experiments this study showed that
CD81 interacts with c-kit on the surface of human CD34+ cord blood HSPCs and
the human growth factor-dependent myeloid cell line, MO7e. C-kit expression on
HSPCs is critical for the maintenance and regulation of HSPC processes.
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Therefore, the interaction of CD81 and c-kit could be important for the regulation
of HSPCs.

1.8.2.3 CD151
The tetraspanin CD151 is expressed within the hematopoietic system on
activated T cells, megakaryocytes and platelets. CD151+ human megakaryocyte
progenitors derived from mobilized peripheral blood were shown to enhance T
helper cell responses (Finkielsztein et al., 2015). In addition, CD151 is also
expressed on the hematopoietic stem cell lines MO7e, HEL and K562 (Fitter et
al., 1999). This study found that CD151 interacts with the integrins β1 and αIIbβ3,
which was found to mediate HSPC adhesion to various extracellular matrices
(ECMs). Together these data indicate that CD151 is used as a HSPC marker and
is important for the regulation of HSPC adhesion via the interaction with integrins.

1.8.2.4 CD63
HSPCs are tightly regulated within the bone marrow microenvironment
through cell-cell interactions mediated by adhesion and signaling molecules.
CD63 was found to be associated with c-kit on the surface of the hematopoietic
progenitor cell line, MO7e (Anzai et al., 2002). The association of c-kit with CD63
could be important for the regulation of HPC functions such as adhesion,
proliferation and migration. The tetraspanin CD63 was described to interact with
the tissue inhibitor of metalloproteinase-1 (TIMP1) to promote cell survival in a
breast cancer cell line model (Jung et al., 2006). The role of TIMP1 in HSCs was
investigated using a TIMP1 knock out mouse, in which TIMP1 was shown to be
important for HSC quiescence and long-term engraftment (Rossi et al., 2011). In
another study, TIMP1 was found to bind to the CD63/beta 1 integrin complex on
the surface of human CD34+ HSPCs to induce adhesion and migration (Wilk et
al., 2013). This group also determined that homing and short term engraftment of
HSPCs were also increased upon exogenous stimulation with TIMP1. The
interaction of TIMP1 and CD63 has also been shown to impact HSPC
proliferation through the activation of the PI3K/AKT signaling pathway (Rossi et
al., 2015). This group also found that TIMP1 treatment of HSPCs led to an
increase in cyclin D1 gene expression due to AKT phosphorylation. Another
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study demonstrated that CD63 and another tetraspanin, CD53, were suggested
to be stringent markers for asymmetric HSC division compared to the current
CD133 and CD34 expression profiles (Beckmann et al., 2007; Giebel and
Beckmann, 2007). Together these studies display an important role for CD63 in
HSPC function and maintenance within the bone marrow microenvironment.

1.8.2.5 CD53
Tetraspanin CD53 is expressed on most immune cells and is expressed
on a small population of hematopoietic stem cells. As stated above, CD53, in
combination with CD63 both served as more stringent markers for asymmetric
division than the current CD133 and CD34 expression profiles (Beckmann et al.,
2007; Giebel and Beckmann, 2007). In addition, another study completed a
comprehensive single-cell gene expression analysis of the mouse hematopoietic
system, in which they found CD53 to be differentially expressed within the HSPC
population (Guo et al., 2013). Moreover, another study has shown that in a
HSPC cell line, CD53 is important for the development of B cells (Mansson et al.,
2007).

1.8.2.6 Tetraspanin 3
The expression of Tetraspanin 3 has been confirmed on HSPCs. A recent
study described Tetraspanin 3 as an important mediator of AML development
and expansion (Kwon et al., 2015). This study also showed that in the normal
hematopoietic system, Tetraspanin 3 expression is dependent on the expression
of the RNA binding protein, Musashi 2. Interestingly, the loss of Tetraspanin 3 led
to a decrease in CXCR4 activity. Together, these data suggest that Tetraspanin
3 could have a potential role in the regulation of HSPC development and
migration.

1.8.2.7 TSSC6 (TSPAN32)
The expression of TSSC6 has been confirmed on HSPCs, but the function
of this tetraspanin has not been fully characterized. TSSC6 has been identified in
the adult hematopoietic tissue of both human and mice (Nicholson et al., 2000;
Robb et al., 2001). Expression of TSSC6 was also confirmed in various
hematopoietic stem cell lines (Robb et al., 2001). The role of TSSC6 in HSPCs
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was assessed using a TSSC6 knock out mouse model, in which steady-state
hematopoiesis was unaltered compared to control mice (Tarrant et al., 2002). In
addition, there was no difference in the hematopoietic system when challenged
with various stimuli. Collectively, this study suggests that TSSC6 is not
necessary for hematopoietic system development, however, a specific role for
TSSC6 in HSPCs has not been fully explored.

1.8.2.8 CD82
The tetraspanin CD82 is ubiquitously expressed and has been described
to interact with different adhesion and signaling molecules on the surface of
HSPCs. A schematic of the CD82 structure is depicted in Figure 1.4. CD82 was
first described on the surface of human HSPCs isolated from peripheral blood
(Burchert et al., 1999). In addition, this group found that CD82 expression is
increased in leukemias such as CML, AML and CLL. However, interestingly the
level of CD82 expression decreased upon differentiation of CD34+ HSPC. CD82
expression and its plasma membrane organization were also found by our group
to mediate the interaction between human CD34+ HSPCs and osteoblasts
(Larochelle et al., 2012). In this study, CD34+ HSPCs were also cell sorted
based on their cell cycle status, which identified the distribution of CD82 in G0
cells. More recently, CD82 expression was shown to be highly expressed on LTHSCs (Hur et al., 2016). This study also determined that CD82 is important for
LT-HSC quiescence, which is mediated through the interaction of CD82 and
DARC via the activation of the TGFB pathway. Together these data suggest an
important

role

for

CD82-mediated

regulation

of

HSPC

differentiation,

maintenance and quiescence.

1.9 Summary and Discussion
The introduction to this thesis intends to provide an overview of key
studies regarding the mechanisms known to regulate HSPC functions such as
quiescence, homing, engraftment and mobilization. However, a few questions
still remain within the field. Previous work from our lab identified the tetraspanin
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Figure 1.4: CD82 structure and posttranslational modifications. This
diagram depicts the structure of CD82. CD82 spans the transmembrane four
times which creates two extracellular loops and one small intracellular loop. In
addition, CD82 contains two intracellular tails, a N-termini and C-termini. CD82
contains five proximal cysteine residues shown in yellow, which can be
palmitoylated. The three asparagine residues shown in green are N-link
glycosylated sites. The C-terminal tail of CD82 consists of a tyrosine based sort
motif (YXXø) shown in orange, which contains amino acids, Tyr-Ser-Lys-Val.
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CD82 as a critical regulator of HSPC function. For example, while a number of
molecules involved in HSPC homing and engraftment have been extensively
studied, the role of CD82 in regulating these functions is still limited. Previous
antibody-based studies (Larochelle et al., 2012) suggest that CD82 is important
for regulating HSPC homing, however, a role for CD82 in HSPC engraftment has
never been described. We hypothesize that the CD82 scaffold promotes HSPC
bone marrow homing and engraftment. In Chapter 2, we utilized a global CD82
knock out (CD82KO) mouse model to test the hypothesis that CD82 promotes
HSPC quiescence, homing and engraftment. We demonstrated that the lost of
CD82 resulted in decreased LT-HSCs, which we believe is due to increased
CD82KO activation. In addition, we determined that the defect in CD82KO HSPC
bone marrow homing was due to hyperactivation of Rac1. We were able to
rescue CD82KO HSPC homing through the use of Rac1 inhibitors. In addition,
we detected a defect in CD82KO HSPC engraftment in a competitive
environment, which could potentially be a result of a defect in CD82KO HSPC
homing.
The molecules and mechanisms that mediate HSPC mobilization has
been extensively studied, however, the role for CD82 has never been described.
In chapter 3, we describe a novel role for CD82 in regulating HSPC mobilization
through the modulation of the sphingoshine-1-phosphate receptor 1 (S1PR1).
Again, using the global CD82KO mouse and flow cytometry techniques, we
hypothesized that the loss of CD82 would promote HSPC mobilization. We were
able to detect enhanced mobilization of CD82KO HSPCs compared to WT
HSPCs. Our data demonstrate that CD82KO HSPCs have enhanced
mobilization due to increased surface expression of S1PR1. In addition,
phosphoflow signaling analysis show increased signaling of pERK and pAKT
downstream of S1PR1 within CD82KO HSPCs. Futhermore, we find a significant
decrease in the internalization of S1PR1 on the surface of CD82KO HSPCs,
which could mechanistically explain the increase in surface expression we
detect. Finally, through the use of a CD82 antibody we were able to increase
HSPC mobilization in WT mice compared to control treatment.
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Collectively, these chapters describe an important role for tetraspanin
CD82 as a critical regulator of HSPC quiescence, homing, engraftment and
mobilization. Chapters 2 and 3 will further describe the important role for CD82 in
mediating these processes. Our work provides evidence that CD82 could be
exploited to increase HSPC homing and engraftment potential. Additionally, we
provide evidence that CD82 could be a valuable target to promote HSPC
mobilization. Taken together, we have identified the tetraspanin CD82 as a
critical regulator of HSPC fitness and function.
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2.1 Abstract
Hematopoietic

stem

and

progenitor

cell

(HSPC)

transplantation

represents a treatment option for patients with malignant and non-malignant
hematological diseases. Initial steps in transplantation involve the bone marrow
homing and engraftment of peripheral blood injected HSPCs. In recent work, we
identified the tetraspanin CD82 as a potential regulator of HSPC homing to the
bone marrow, although its mechanism remains unclear. In the present study,
using a CD82 knock out (CD82KO) mouse model, we determined that CD82
modulates HSPC bone marrow maintenance, homing and engraftment. Bone
marrow characterization identified a significant decrease in the number of longterm hematopoietic stem cells in the CD82KO mice, which we linked to cell cycle
activation and reduced stem cell quiescence. Additionally, we demonstrate that
CD82 deficiency disrupts bone marrow homing and engraftment, with in vitro
analysis identifying further defects in migration and cell spreading. Moreover, we
find that the CD82KO HSPC homing defect is due at least in part to the
hyperactivation of Rac1, as Rac1 inhibition rescues homing capacity. Together,
these data provide evidence that CD82 is an important regulator of HSPC bone
marrow maintenance, homing and engraftment and suggests exploiting the CD82
scaffold as a therapeutic target for improved efficacy of stem cell transplants.

2.2 Introduction
Hematopoietic stem and progenitor cells (HSPCs) provide the cellular
reservoir that gives rise to the highly varied blood and immune cells required to
support the lifespan of an organism. As such, it is necessary that HSPCs
maintain a finely tuned balance between quiescence, self-renewal, proliferation
and differentiation. While key signaling pathways intrinsic to HSPCs are involved
in regulating this delicate balance, HSPCs are also regulated by a variety of
signals they receive from their microenvironment or niche. The bone marrow
microenvironment is the primary residence for HSPCs, where they are regulated
by both secreted signals and cell-cell interactions (Mendelson and Frenette,
2014; Morrison and Scadden, 2014; Morrison and Spradling, 2008). Under
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physiological conditions, HSPCs are maintained in the bone marrow, but also
circulate within the blood at low levels (Mazo and von Andrian, 1999; Sahin and
Buitenhuis, 2012). Then from the peripheral blood, the HSPCs can migrate back
to the bone marrow using a process called homing, which is the critical first step
in the repopulation of the bone marrow after stem cell transplantation. Currently,
allogeneic hematopoietic stem cell (HSC) transplantation is a standard treatment
option for patients suffering from a variety of malignant and non-malignant
hematological diseases (Gyurkocza et al., 2010). The effectiveness of this
treatment requires the successful homing of donor HSPCs back to the bone
marrow microenvironment, where they can engraft and repopulate the blood and
immune cell lineages. Notably, only a small percentage of transplanted HSPCs
have the capacity to engraft, and while graft failure is rare, it remains a significant
contributor to patient morbidity and mortality (Ratajczak and Suszynska, 2016).
With the ultimate goal of improving transplantation therapies, there is significant
interest in understanding the molecular mechanisms that regulate the
repopulation potential or fitness of HSPCs, which requires productive bone
marrow homing and engraftment.
HSPC bone marrow homing is a dynamic process, which includes various
adhesion and signaling molecules such as chemokines and integrins. The
chemokine CXCL12 is an important chemoattractant and regulator of HSPCs.
The expression and secretion of CXCL12 is abundant in the bone marrow
microenvironment (expressed by osteoblasts and endothelial cells) and promotes
the homing and maintenance of HSPCs within the bone marrow. The receptor for
CXCL12 is the C-X-C Chemokine receptor type 4 (CXCR4) receptor, which is
highly expressed on HSPCs and controls HSPC homing, mobilization and niche
localization (Nie et al., 2008; Prosper and Verfaillie, 2001; Sahin and Buitenhuis,
2012). The loss of CXCR4 on HSPCs results in a significant decrease in HSPC
homing to the bone marrow (Nie et al., 2008). Interestingly, the re-expression of
CXCR4 restored hematopoiesis upon bone marrow engraftment. In addition,
integrins such as α4, α6, and β1 facilitate adhesion in the bone marrow, but also
mediate tethering of HSPCs within blood vessels to enable trans-endothelial
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HSPC migration (Mazo and von Andrian, 1999; Papayannopoulou et al., 1995;
Papayannopoulou et al., 2001a). The treatment of bone marrow HSPCs with an
antibody to α4β1 resulted in decreased bone marrow homing (Papayannopoulou
et al., 1995; Papayannopoulou et al., 2001a). In addition, bone marrow cells from
a conditional α4 KO mouse showed a delay in bone marrow homing and defect
in short-term engraftment (Scott et al., 2003). Similarly, HSPCs deficient in the
integrin β1 (Hirsch et al., 1996; Potocnik et al., 2000) and treatment of bone
marrow cells with an α6 antibody (Qian et al., 2006) led to a decrease in bone
marrow homing and engraftment. Together, these data highlight the critical role
for integrins and the CXCR4/CXCL12 signaling axis in HSPC homing and
engraftment. Thus, understanding how these signaling and adhesion pathways
are regulated in HSPCs is critical for improved transplantation therapies.
Tetraspanins are a family of scaffold proteins that are known to regulate
adhesion and signaling molecules at the plasma membrane (Boucheix and
Rubinstein, 2001; Hemler, 2005). Tetraspanins have an evolutionary conserved
structure that spans the plasma membrane four times and interact with other
tetraspanins, signaling and adhesion molecules to form tetraspanin-enriched
microdomains (TEMs) that are important for modulating cell migration and
adhesion (Charrin et al., 2009; van Deventer et al., 2017). Previous work from
our lab identified the tetraspanin CD82 as a potential regulator of HSPC
adhesion and migration, demonstrating that human CD34+ HSPC bone marrow
homing was diminished when CD82 was neutralized with a monoclonal antibody
(Larochelle et al., 2012). CD82 was first described as a tumor metastasis
suppressor in solid tumors (Bienstock and Barrett, 2001) and is expressed in
both normal and malignant hematopoietic cells (Burchert et al., 1999). Using an
acute myeloid leukemia (AML) cell line model, our laboratory also identified
decreased bone marrow homing upon CD82 knock down (Marjon et al., 2016)
and went on to show that CD82 regulates the density of the α4 integrin at the
plasma membrane, which contributes significantly to HSPC adhesive potential
(Termini et al., 2014). More recently, CD82 was shown to be highly expressed on
the long-term hematopoietic stem cell population (LT-HSCs) with a potential role
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in the regulation of HSPC quiescence (Hur et al., 2016). In this current study, we
set out to determine how CD82 impacts the homing and engraftment of HSPCs.
Using a global CD82 knock out (CD82KO) mouse model, we identify a
reduction in the LT-HSCs localized within the bone marrow compartment, which
we find results from LT-HSC activation. Moreover, measurements of HSPC
fitness identified both engraftment and homing defects upon CD82 deficiency.
Isolated HSPCs analyzed by confocal imaging demonstrated additional defects in
migration and cell spreading. Recognizing the critical role for the Rho GTPase,
Rac1, in cell migration and spreading, we analyzed the expression and activity of
Rac1, finding Rac1 hyperactivation in CD82KO HSPCs. Inhibition of Rac1
hyperactivation using pharmacological inhibitors restored the bone marrow
homing capacity of the CD82KO HSPCs, suggesting that CD82-mediated
regulation of HSPC homing and engraftment involves the modulation of Rac1
activity.

2.3 Results
2.3.1 Diminished LT-HSCs within the bone marrow of CD82KO
mice.
To understand the mechanism by which the CD82 scaffold impacts HSPC
regulation, we took advantage of the CD82KO mice previously described (Jones
et al., 2016; Wei et al., 2014). To address the consequence of CD82KO on
HSPC homeostasis, we first compared the bone marrow frequencies of HSPCs
in the wild-type (WT) and CD82KO mice. Using flow cytometry, we observed a
reduction in the frequency of long-term HSCs (LT-HSCs), defined as LinSca1+Kit+CD34-CD135-CD48-CD150+, in CD82KO, whereas short-term HSCs
(ST-HSCs: Lin-Sca1+Kit+CD34+CD135-CD48-CD150+), multipotent progenitors
(MPP:

Lin-Sca1+Kit+CD34+CD135+CD48-CD150-),

and

LSK

(Lin-Sca1+Kit+)

populations showed no significant change (Figure 1A,B). Further characterization
of the immune phenotype of bone marrow isolated cells identified similar
percentages of B cells, T cells and myeloid cells between the WT and CD82KO
mice (Figure 1C). Together, these data suggest that CD82 functions in the
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Figure 2.1: CD82 expression maintains LT-HSCs within the bone marrow.
(A) Representative flow cytometry plots of LT-HSCs gated on the LSK CD135CD34-CD48-CD150+ population. Flow cytometry analysis of the percentage of
MPP, ST-HSC and LT-HSCs from the bone marrow LSK population of WT and
CD82KO mice. Error bars, SEM; n=8-9 mice per strain (***p<0.001). (B) Flow
cytometry analysis of the percentage of the LSK population from WT and
CD82KO mice. n=8 mice per strain. (C) Flow cytometry analysis of the
percentage of immune cells (B cells (B220), T cells (CD3) and myeloid cells
(Gr1/Mac1)) within the bone marrow of WT and CD82KO mice. n=15 mice per
strain. (D) Flow cytometry plots of DNA (Hoechst) and the proliferative nuclear
antigen (Ki-67) expression of the bone marrow to measure the cell cycle status of
LT-HSC population from WT and CD82KO mice. Error bars, SEM; n=3
independent experiments (*p<0.05 and **p<0.01). (E) Flow cytometry analysis of
BrdU expression in the LT-HSC population after 3 days of BrdU incorporation in
vivo. Error bars, SEM; n=3 independent experiments (**p<0.01).
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maintenance of the LT-HSC population.
To address the cause of the reduction in LT-HSCs in the CD82KO bone
marrow, we first analyzed extramedullary tissues and identified no increase in the
number of LT-HSCs in CD82KO mice (data not shown). Therefore,
extramedullary hematopoiesis does not appear to contribute to the observed
reduction in bone marrow LT-HSCs. Next, we analyzed the proliferation and cell
cycle status of CD82KO LT-HSCs. Combining the Ki67 marker with DNA content
analysis, we find that CD82KO LT-HSCs increase cell cycle entry (Figure 1D).
We also completed bromodeoxyuridine (BrdU) incorporation assays to assess
proliferation changes in vivo, identifying a significant increase in BrdU+ LT-HSCs
within the bone marrow of CD82KO mice (Figure 1E). These data suggest that
the cell cycle activation of the CD82KO LT-HSCs ultimately results in the
reduction of the quiescent LT-HSC population localized to the bone marrow.
Collectively, these data are consistent with a previous study using an alternative
CD82KO mouse model, which described a similar reduction in the LT-HSCs,
resulting from cell cycle entry (Hur et al., 2016).

2.3.2 Reduced competitive repopulation capacity of CD82KO
HSPCs.
To assess how CD82 deficiency impacts stem cell repopulation, we
carried out long-term engraftment assays where we analyzed the reconstitution
ability of WT and CD82KO HSPCs. Using a congenic mouse system, we
transplanted donor WT or CD82KO Lin- HSPCs into lethally irradiated recipients
(Figure 2A). The B6.SJL-Ptprca Pepcb/BoyJ (CD45.1) mouse strain was used as
recipients because they carry the differential pan leukocyte marker CD45.1,
which can be distinguished from the WT and CD82KO donor cell populations that
express the CD45.2 allele. Monthly peripheral blood analysis confirmed a similar
engraftment of both CD82KO and WT donor-derived CD45.2 cells (Figure 2B).
Additionally, analysis of the immune cell phenotype of the recipient mice
identified no significant changes in the production of B, T, or myeloid cells (Figure
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Figure 2.2: CD82KO HSPCs display decreased repopulation in a
competitive environment. (A) Experimental scheme for the non-competitive
repopulation experiment. (B) The percentage of donor cell repopulation of
peripheral blood collected monthly from tail bleeds. Donor cell chimerism
(CD45.2) status measured via flow cytometry. n=6 mice per strain. (C) Flow
cytometry analysis of the percentage of donor immune cells (B cells (B220), T
cells (CD3) and myeloid cells (Gr1/Mac1)) from donor (CD45.2) population in
figure 2C. (D) Experimental scheme for the competitive repopulation experiment.
(E) Representative flow cytometry plot for the competitive repopulation assay
gated for donor cells (WT, CD45.1 and CD82KO, CD45.2) in the peripheral blood
recipient mice. (F) The percentage of donor cell repopulation of peripheral blood
collected monthly from tail bleeds. Donor cell chimerism (WT, CD45.1 and
CD82KO, CD45.2) status measured via flow cytometry. Error bars, SEM; n= 7
mice per strain (***p<0.001 and ****p<0.0001). (G) Flow cytometry analysis of the
percentage of donor immune cells (B cells (B220), T cells (CD3) and myeloid
cells (Gr1/Mac1)) from donor population in figure 2F. Error bars, SEM; n= 7 mice
per strain (*p<0.05, **p<0.01, and ***p<0.001).
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2C). Therefore, CD82KO HSPCs have the capacity to repopulate a recipient and
generate similar percentages of differentiated immune cells.
Next, we went on to assess the long-term engraftment potential of
CD82KO HSPCs when transplanted into a competitive environment. Isolated LinHSPCs were harvested from WT (CD45.1) and CD82KO (CD45.2) donors and
transplanted into lethally irradiated chimeric mice (CD45.1/CD45.2) at a ratio of
1:1 (Figure 2D). The use of chimeric mice enables us to distinguish the WT
(CD45.1) and the CD82KO (CD45.2) donor cells from the CD45.1/.2 recipient
cells by flow cytometry. After transplant, blood cell chimerism was analyzed
monthly using flow cytometry to measure repopulation. Under these competitive
conditions, we identify a significant decrease in the repopulation capacity of
CD82KO derived cells (CD45.2) when compared to WT cells (CD45.1) (Figure
2E). These data suggest that while CD82KO HSPCs have the capacity to
successfully engraft, when co-transplanted with WT HSPCs, CD82KO HSPCs
display a decreased efficiency to reconstitute a recipient, indicating an overall
reduction in HSPC fitness (Figure 2F). Additionally, we analyzed the immune cell
differentiation potential of competitively engrafted HSPCs identifying a significant
decrease of B and T cells derived from CD82KO HSPCs when compared to WT
HSPCs (Figure 2G). Interestingly, we detect a significant increase in the amount
of CD82KO-derived myeloid cells when compared to WT cells (Figure 2G), which
suggests that CD82KO HSPCs present a myeloid skewing phenotype following
competitive repopulation.

2.3.3 CD82KO HSPCs displayed reduced bone marrow homing.
Successful competitive repopulation requires the initial migration or
homing of HSPCs to the bone marrow. Therefore, we next evaluated how
CD82KO contributes to the early steps of HSPC repopulation by performing a
competitive homing experiment (Figure 3A). Total bone marrow (Figure 3B) or
Lin- cells (Figure 3C) were harvested from CD82KO (CD45.2) and WT (CD45.1)
mice and transplanted into lethally irradiated chimeric mice (CD45.1/CD45.2) at a
ratio of 1:1. The blood and bone marrow of recipient mice were harvested 16
hours post injection to assess the chimerism status using flow cytometry.
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Figure 2.3: CD82KO HSPCs demonstrate decreased bone marrow homing.
(A) Experimental scheme for the competitive homing experiment. (B) The
percentage of total bone marrow and (C) lineage negative donor cells homed
within the blood and bone marrow 16hrs post injection. Donor cell chimerism
(WT, CD45.1 and CD82KO, CD45.2) status measured via flow cytometry. Error
bars, SEM; n= 8-12 mice per strain (*p<0.05, ***p<0.001 and ****p<0.0001). (D)
Experimental scheme for the non-competitive homing experiment. (E) The
percentage of total bone marrow homed within the blood and bone marrow 16 hr
post injection. Donor cell chimerism (CD45.2) status measured via flow
cytometry. Error bars, SEM; n= 5-7 mice per strain (*p<0.05 and ****p<0.0001).
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Analysis of the bone marrow indicates a significant decrease in the number of
CD82KO cells that migrate to the bone marrow when compared to WT cells.
Consistent with the decrease in bone marrow homing, we measure a
significant increase in the number of CD82KO cells detected within the blood
when compared to WT cells. Additionally, we completed homing experiments
with total bone marrow injected into a non-competitive environment (Figure 3D),
identifying a similar homing defect with the CD82KO cells as that observed in the
competitive environment (Figure 3E). Together, these data suggest that the
reduced competitive repopulation capacity of the CD82KO HSPCs is likely due to
the reduced bone marrow homing potential of these cells.

2.3.4 CD82KO does not impact CXCR4 expression or activity.
The CXCR4-CXCL12 signaling axis is a critical regulator of HSPC homing
to and maintenance within the bone marrow. CXCR4 is highly expressed on
HSPCs and serves as the chemokine receptor for CXCL12, which is produced by
bone marrow stromal cells and controls HSPC homing, mobilization and
localization (Nie et al., 2008; Prosper and Verfaillie, 2001; Sahin and Buitenhuis,
2012). To determine if the reduced homing behavior observed with the CD82KO
HSPCs is due to changes in the expression of CXCR4, we measured the surface
expression of CXCR4 by flow cytometry. In Figure 4A we detect no difference in
the CXCR4 mean fluorescence intensity between CD82KO and WT LSKs.
Recognizing that CXCR4 is internalized following activation, we also fixed and
permeabilized WT and CD82KO LSKs to measure total CXCR4 expression.
Similar to the surface expression, we find no difference in mean fluorescence
intensity between CD82KO and WT LSK HSPCs, indicating no changes in
overall CXCR4 expression (Figure 4B).
In addition to modulating the surface expression of membrane proteins,
tetraspanins also have the capacity to cluster membrane-associated proteins
promoting their activation (Marjon et al., 2016; Termini et al., 2016). As such, we
went on to evaluate CXCR4 signal transduction downstream of CXCL12
activation with a focus on AKT and ERK signaling. Phosphoflow cytometry of
phosphorylated AKT and ERK revealed no change in the basal or tonic signaling
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Figure 2.4: CD82KO does not impact CXCR4 expression or activity.
Representative histograms of (A) Surface and (B) total (permeablized) CXCR4
expression of bone marrow HSPCs from WT and CD82KO mice. Flow cytometry
analysis measured the mean fluorescence intensity (MFI) of CXCR4 on the LSK
population. Phosphoflow cytometry analysis of (C) basal and (D) tonic (1hr serum
starvation) conditions to assess the mean fluorescence intensity (MFI) of pAKT,
pERK and total ERK signaling of the LSK population. n= 3 mice per strain. (E)
Phosphoflow cytometry analysis of SDF-1 treatment at various time points post
1hr of serum starvation to assess pAKT, pERK and total ERK signaling of the
LSK population. Quantification ratio calculated by dividing tonic signaling by
SDF-1 treatment conditions. n= 3 mice per strain.
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levels between WT or CD82KO LSKs (Figure 4C and Figure 4D). Moreover,
following

CXCL12

stimulation,

we

detected

similar

AKT

and

ERK

phosphorylation, indicating no difference in CXCR4 activity between WT and
CD82KO LSKs (Figure 4E). Taken together, the CD82KO homing defect does
not result from altered CXCR4 expression or activation.

2.3.5 CD82KO HSPCs display a disruption in migratory behavior.
To further evaluate the mechanism by which CD82KO HSPCs have
reduced capacity to home and engraft, HSPC migration was assessed in vitro.
Lin- HSPCs were isolated from CD82KO and WT mice and imaged by live cell
confocal microscopy. The time-lapse images were analyzed using the Imaris
Tracking Software to obtain measurements of track speed, displacement and
length for individual HSPCs. Figure 5A illustrates that isolated CD82KO HSPCs
have a significant decrease in track speed, track displacement, and track length,
when compared to WT HSPCs. Moreover, single-cell trajectory rose-plots
indicate that CD82KO HSPC track movements are short and consolidated at the
point of origin and lack directional movement, when compared to WT HSPC
tracks (Figure 5B). These data demonstrate a 2D migratory defect for CD82KO
HSPCs, which is consistent with the observed disruption in homing behavior, and
further implicates an important role for CD82 in HSPC migration.
Adhesive strength and cell spreading play key roles in generating the
required traction for cell migration. Therefore, we next measured the cell
spreading capacity of WT and CD82KO cells plated on specific extracellular
matrices. Isolated Lin- HSPCs were plated on either fibronectin or laminin for 4
hours before being fixed and fluorescently labeled with the cytoskeletal marker
phalloidin. Confocal microscopy images were analyzed using ImageJ software to
quantify the area of cell spreading. In Figures 5C and 5D, we measure a
significant increase in the area of CD82KO Lin- HSPCs plated on fibronectin or
laminin when compared to WT HSPCs. To further assess the role of CD82
deficiency in HSPC adhesion, we quantified the surface expression of specific
adhesion molecules, including integrins α4, α6, β1 and CD44. Flow cytometry
analysis of the CD82KO LSK HSPCs measured a significant decrease in mean
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Figure 2.5: CD82KO HSPCs display decreased migration and increased cell
spreading. (A) Live cell confocal imaging analysis of HSPC migration from WT
and CD82KO bone marrow. IMARIS imaging software was used to assess track
speed, track displacement and track length. Error bars, SEM; n= 2 independent
experiments (**p<0.01). (B) Rose plots were generated using the WT and
CD82KO HSPC track length coordinates. Cell spreading potential of isolated WT
and CD82KO HSPCs plated on (C) fibronectin and (D) laminin. Representative
images show actin staining used to quantify HSPC area using ImageJ software.
Error bars, SEM; n= 2 independent experiments (**p<0.01 and ***p<0.001). (E)
Representative histograms of surface adhesion molecule expression of bone
marrow HSPCs from WT and CD82KO mice. Flow cytometry analysis measuring
the mean fluorescence intensity (MFI) of each adhesion molecule on the LSK
population. Error bars, SEM; n= 3 mice per strain (*p<0.05 and ****p<0.0001).
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fluorescent intensity of α6, and a modest decrease in β1, with no mean fluorescent
intensity changes detected for α4 and CD44 when compared to WT HSPCs
(Figure 5E). Collectively, the decreased surface expression of integrins α6 and β1
and the enhanced cell spreading likely contribute to the decrease in homing and
engraftment potential seen with the CD82KO HSPCs.

2.3.6 CD82KO HSPCs have increased Rac1-GTPase activity.
Rho GTPases play an essential role in cell spreading and cell migration.
Moreover, previous studies have demonstrated that the specific RhoGTPase,
Rac, can control hematopoietic stem cell activities such as marrow homing and
retention (Cancelas et al., 2005; Dorrance et al., 2013; Gu et al., 2003; Liu et al.,
2011b; Shang et al., 2011; Williams et al., 2008; Yang et al., 2001). Based on the
increased cell spreading observed in Figures 5C,D, by the CD82KO cells, we set
out to measure Rac1 expression and activity. Western blot analysis of total bone
marrow suggests no change in Rac1 expression when comparing WT and
CD82KO cells (Figure 6A). Additional flow cytometry analysis of the LSK cells
also indicates no difference in Rac1 expression when comparing WT and
CD82KO cells (Figure 6B). Similarly, we were unable to detect any changes in
Rac1 gene expression between WT and CD82KO mice when analyzing either
the total bone marrow or the Lin- fraction of HSPCs (Figure 6C). Recognizing that
Rac activity is a key contributor to cell spreading, we went on to measure
changes in Rac1 activity by flow cytometry using an active Rac1-specific
antibody. Figure 6D indicates that the CD82KO LSK HSPCs have increased
Rac1 activity when compared to WT cells. A similar result was measured using
an active Rac1 ELISA activation assay, where we identified a significant increase
in the active form of Rac1 in the CD82KO Lin- bone marrow lysates when
compared to WT (Figure 6E). Collectively, these data suggest that while CD82
deficiency does not impact overall Rac1 expression, Rac1 hyperactivation is
detected in the HSPCs upon CD82KO. Lastly, we wanted to determine whether
the measured increase in Rac1 activity contributes to the disruption in cell
migration and bone marrow homing observed with the CD82KO HSPCs. As
such, we completed cell migration studies of the CD82KO Lin- HSPCs that were

65

66

67

Figure 2.6: Rac1 hyperactivity in the CD82KO HSPCs contributes to
diminished HSPC homing. (A) Western blot analysis of WT and CD82KO total
bone marrow measuring Rac1 expression. Densitometry was used to quantify
Rac1 expressionmrelative to an actin control. n=3 independent experiments. (B)
Representative histogram of surface Rac1 expression. Flow cytometry analysis
measured the MFI of Rac1 on the LSK population. n=3 mice per strain. (C) Rac1
mRNA expression of total bone marrow and FACS sorted lineage negative cells
using Real Time qPCR. Rac1 expression was normalized to GAPDH to obtain
relative quantification (RQ) values. n= 3 independent experiments. (D)
Representative histogram of Rac GTP expression. Flow cytometry analysis
measured Rac GTP on WT and CD82KO lineage negative bone marrow cells.
(E) Rac1 activity of WT and CD82KO lineage negative cells measured using
GLISA assay. Quantification represents fold change relative to WT. Error bars,
SEM;n= 3 independent experiments (**p<0.01). (F) Live cell confocal imaging
analysis of HSPC migration from WT and CD82KO bone marrow. CD82KO
HSPCs were treated with EHOP-016 1hr prior to migration.
IMARIS software was used to assess track speed. Error bars, SEM; n=2
independent experiments, One-Way ANOVA (*p<0.05 and n.s.,non-significant).
(G) The percentage of total bone marrow cells homed within bone marrow 16rs
post injection. Total bone marrow were treated with EHOP-016 or NSC23766 1hr
prior to injection. Donor cell chimerism (CD45.2) status was measured via flow
cytometry. Error bars, SEM; n= 5-13 mice per strain, One-Way ANOVA (*p<0.05
and n.s., non significant).
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treated with and without the Rac1- specific inhibitor EHOP-016. Analysis of track
speed indicates that inhibition of Rac1 hyperactivation restores the velocity of the
CD82KO HSPCs to WT HSPC speeds (Figure 6F). Moreover, we completed the
bone marrow homing experiments with WT and CD82KO total bone marrow,
where we also pretreated cells with EHOP-016 or another Rac1 inhibitor,
NSC23766 for 1 hr prior to injection. Bone marrow was isolated 16 hr after
injection and analyzed as previously described. Again, we measure a decrease
in bone marrow homing of CD82KO cells when compared to WT cells. Moreover,
we find that WT cells pretreated with the Rac1 inhibitor NSC23766 display a
significant reduction in bone marrow homing, consistent with previous reports
establishing the importance of Rac1 in HSC migration (Cancelas et al., 2005;
Dorrance et al., 2013; Gu et al., 2003; Liu et al., 2011b; Yang et al., 2001). In
contrast, when Rac1 hyperactive CD82KO cells were pretreated with Rac1
inhibitors, bone marrow homing capacity was restored to WT levels (Figure 6G).
Taken together, CD82 deficiency inhibits HSPC migration to the bone marrow at
least in part by promoting a shift in the balance of Rac1 activity to a
hyperactivated state.

2.4 Discussion
Successful clinical outcomes from transplantation depend upon the
efficient bone marrow homing and engraftment of HSPCs. The current study
analyzing HSPCs from CD82KO mice provides strong evidence that the
tetraspanin CD82 regulates the maintenance of LT-HSCs within the bone marrow
as well as both processes of homing and engraftment. Moreover, if we inhibit the
activation of the Rac1 GTPase in the CD82KO HSPCs, we recover the homing
defect observed upon loss of CD82. These results have led us to propose a
model whereby the CD82 scaffold functions to 1) promote bone marrow niche
interactions that maintain cell cycle quiescence and 2) enhance the bone marrow
homing required for HSPC engraftment through the modulation of Rac1
activation.
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Regulation of HSPC activation has been described for a number of
tetraspanins. For example, tetraspanin CD81 was shown to be important for the
re-entry of HSCs to quiescence through the inhibition of AKT signaling pathway
(Lin et al., 2011). The polarized organization of CD81 on the surface of murine
HSCs led to the deactivation of AKT and nuclear translocation of FoxO1a, which
was important for the re-entry of HSCs into quiescence from a highly proliferative
state. This study also demonstrated that CD81KO HSCs have a marked
engraftment defect. Previous work by Rossi et al. also demonstrated a role for
tetraspanin CD63 in the regulation of HSPC proliferation through its interaction
with tissue inhibitor of metalloproteinase-1 (TIMP1) and the activation of the
PI3K/AKT signaling pathway (Rossi et al., 2015). Furthermore, they found that
upon TIMP1 treatment of HSPCs, cyclin D1 gene expression was increased
downstream of AKT phosphorylation. Previous work from our group identified a
correlation between CD82 membrane organization and cell cycle progression
(Larochelle et al., 2012), where CD34+ HSPCs sorted based on the G0 cell cycle
stage showed a polarized membrane distribution of CD82, suggesting that CD82
organization may also impact HSPC quiescence. More recently, a CD82KO
mouse model was used to identify CD82 as an important regulator of LT-HSC
quiescence (Hur et al., 2016). In this study, a cell line system was predominantly
used to describe a mechanism where CD82 binds to the Duffy antigen receptor
complex on bone marrow macrophages downstream of TGFβ activation to
modulate LT-HSC quiescence. In our own study, we use an alternative CD82KO
mouse model that was previously described (Jones et al., 2016; Wei et al., 2014)
and identify a similar LT-HSC defect with the loss of CD82. Our cell cycle
activation studies demonstrating a loss of LT-HSC quiescence, nicely parallel the
findings of the Hur et al. study. However, we then went on to characterize the
fitness of the CD82KO HSPCs, further identifying homing and engraftment
defects.
Once introduced into the blood stream, HSPCs have the capacity to
migrate back to the bone marrow in a process that involves intercellular signaling
and adhesive interactions (Caocci et al., 2017; Vermeulen et al., 1998). The
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major

chemokine

signal

responsible

for

this

homing

process

is

the

CXCR4/CXCL12 signaling axis. As mentioned previously, CXCR4 on the surface
of HSPCs migrates toward its ligand, CXCL12, produced within the bone marrow.
Recognizing the critical importance of this receptor/ligand interaction in homing,
we thoroughly investigated the potential influence of CD82KO on receptor
expression and activation. However, we demonstrate that CD82 deficiency
results in no significant impact on CXCR4 expression or activation. Therefore,
the observed CD82-mediated homing defect appears to occur through an
alternative mechanism, which led us to analyze in vitro adhesion and migration
behaviors.
Tetraspanin-tetraspanin and tetraspanin-integrin interactions are known to
regulate adhesion and migration in a variety of different biological systems.
Focusing in on HSPCs specifically, the tetraspanin CD63 in complex with TIMP1
and the β1 integrin were shown to modulate adhesion and migration of human
CD34+ HSPCs (Wilk et al., 2013). Moreover, the tetraspanin CD9 was shown to
regulate HSPC migration and adhesion, although its role in homing remains a bit
unclear. In the initial study described by Leung et al., CD9 expression on human
cord blood CD34+ HSPCs was shown to be modulated by SDF-1 and CXCR4
activity, resulting in increased HSPC migration and adhesion (Leung et al.,
2011). Additionally, this group went on to show that enhancing CD9 expression
on the surface of CD34+ HSPCs with the treatment of a protein kinase C agonist
ε, ingenol 3,20 dibenzoate (IDB), increases homing to the bone marrow.
However, in a follow up study, Desmond et al. found that while IDB increases
CD9 expression on CD34+ HSPCs, it does not increase HSPC homing
compared to control treated CD34+ HSPCs intravenously injected into NSG mice
(Desmond et al., 2011). Our own work with CD82 demonstrated that human
CD34+ HSPC pretreatment with a CD82-specific neutralizing antibody
significantly reduced bone marrow homing of these cells in an animal model
(Larochelle et al., 2012). In the current study, we identify a significant defect in
the bone marrow homing and engraftment capacity of CD82KO HSPCs,
demonstrating a clear role for CD82 in these two processes. We also detect a
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myeloid skewing phenotype, which is consistent with a HSPC aging phenotype
(Liang et al., 2005; Rossi et al., 2005). Interestingly, aged HSPCs are also known
to have reduced bone marrow homing and engraftment capabilities (Liang et al.,
2005; Morrison et al., 1996), which suggests that CD82 may impact HSPC aging.
Once injected into the peripheral blood, homing is the initial process that
enables the HSPCs to traffic to the bone marrow, where the cells will ultimately
engraft and repopulate the blood and immune cell lineages. Despite the clear
homing defect we observe with the CD82KO HSPCs, it is interesting to note that
non-competitive engraftment assays illustrate no detectable impact of CD82
expression. Only in a competitive environment do we identify a significant
disruption in repopulation. These data suggest that perhaps CD82KO HSPCs
have a reduced rate of migration and homing, however, when given unlimited
time, as in the non-competitive engraftment, the CD82KO cells will eventually
make their way to the bone marrow where they have the capacity to repopulate.
Conversely, in a competitive environment, the WT HSPCs home more efficiently
to the bone marrow, where they perhaps fill many of the available niche sites,
reducing the engraftment capabilities of the CD82KO HSPCs with delayed bone
marrow homing. These data are further supported by the in vitro migration data in
Figure 5, where CD82KO cells display reduced 2D migration. Additionally, we
find that CD82KO promotes increased cell spreading, which likely contributes to
the reduction in cell migration. Previous work focusing on bone marrow-derived
dendritic cells from the CD82KO mice identified a similar cell spreading defect
when plated on fibronectin (Jones et al., 2016). Moreover, they went on to show
altered GTPase activities in the CD82KO cells illustrating an important role for
tetraspanins in the regulation of GTPase activity.
Tetraspanins can interact with Rho GTPases at the plasma membrane
and mediate downstream signaling (Termini and Gillette, 2017). In fact, evidence
in the literature suggests that tetraspanins are important for the regulation of both
Rac1 expression and activity. For example, the overexpression of CD82 was
shown to inhibit Rac1 activity resulting in actin disorganization (Liu et al., 2012b),
whereas the interaction of Rac1 with the c-terminal tail of CD81 led to an overall
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decrease in Rac1 expression (Tejera et al., 2013). Similarly, tetraspanins CD9
and CD151 are both implicated in the activation of Rac1 (Arnaud et al., 2015;
Hong et al., 2012). The Rho family GTPases function as molecular switches that
can coordinate cytoskeletal rearrangements, which ultimately impact a range of
cellular behaviors including migration and adhesion. Among the Rho family
GTPases, Rac is known to play a clear role in HSPCs migration and homing
(Cancelas et al., 2005; Dorrance et al., 2013; Gu et al., 2003; Liu et al., 2011b;
Ridley, 2001; Shang et al., 2011; Williams et al., 2008; Yang et al., 2001).
Conditional knock out mouse studies for Rac1 demonstrated both impaired
HSPC engraftment and reduced adhesion to fibronectin (Gu et al., 2003).
Similarly, knock out of the HSPC specific Rac2 identified defects in actin
cytoskeleton remodeling and α4β1-mediated adhesion (Yang et al., 2001).
Interestingly, in the case of Rac2 deficiency, HSPCs showed increased migration
toward a CXCL12 gradient, which the authors suggest may be the result of
compensatory upregulation of Rac1 and Cdc42 activities (Yang et al., 2001).
Collectively, these studies illustrate the significant impact of Rac knock out on
HSPCs, but much less is known about how Rac hyperactivation alters
phenotype. In a recent study, c-Kit+ HSPCs overexpressing a constitutively
active form of Rac1 GTPase (Rac1 V12) displayed increased cell migration and
adhesion (Chen et al., 2016). In contrast, a study by Shang et al, modulated
endogenous Rac1 activation through manipulation of R-Ras expression and
identified diminished bone marrow homing of HSPCs upon Rac1 hyperactivation
(Shang et al., 2011). Our studies measuring changes in endogenous Rac1
activation identified a similar defect in bone marrow homing of HSPCs when
Rac1 is hyperactive. These data suggest that once Rac1 activity goes beyond a
certain threshold, cell migration is diminished. Previously, when Rac inhibitors
have been used, decreased cell migration and adhesion are observed (Chen et
al., 2016; Montalvo-Ortiz et al., 2012). Even in our own studies, we find that WT
HSPC homing is decreased upon treatment with the Rac1 inhibitor, NSC23766.
In contrast, the use of two different Rac1 inhibitors restored the bone marrow
homing deficit of the CD82KO HSPCs. We speculate that upon Rac1
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hyperactivation, the inhibitor reduces the Rac1 activity threshold, resulting in
baseline migration and adhesion. However, when inhibitors are used to disrupt
basal Rac1 activity, an overall reduction in migration and adhesion is observed
(Chen et al., 2016; Montalvo-Ortiz et al., 2012). Together, these data highlight
the importance of the tight regulation of a Rac1 activity threshold to maintain
HSPC fitness. At this time, how the CD82 scaffold functions to regulate Rac1
activity remains unclear. While there is precedence from the literature that direct
interactions can occur between tetraspanins and GTPases (Arnaud et al., 2015;
Hong et al., 2012; Liu et al., 2012b; Tejera et al., 2013), we speculate that CD82
is more likely to modulate a Rac1 regulator, and thus affect Rac1 activity
indirectly. For example, our own work has established a role for CD82 in the
regulation of adhesion molecules a4b1 and N-cadherin (Marjon et al., 2016;
Termini et al., 2014), which can both modulate Rac activation (Arthur et al., 2002;
Rose, 2006; Rose et al., 2007). Additionally, the tetraspanin CD151 was shown
to facilitate interactions between the a3b1 and a6b1 and several small GTPases
(Hong et al., 2012). Alternatively, the modulation of specific guanine nucleotide
exchange factors (GEFs) and GTPase-activating proteins (GAPs) can also have
a significant impact on small GTPase activity (Lawson and Burridge, 2014).
Therefore, future studies will be directed at understanding how CD82 potentially
modulates the expression and/or activity of key regulators of Rac1 activation.
The goal of the current study is to identify the mechanism by which CD82
regulates HSPC fitness with a focus on bone marrow homing and engraftment.
Our data suggest that CD82 can not only modulate the activation of LT-HSCs,
but also the overall fitness of HSPCs. Activation of LT-HSCs is likely related to
how tightly HSPCs interact with specific components of the bone marrow
microenvironment, although at this point, it is unclear how CD82KO impacts
cellular localization within the niche. HSPC fitness is characterized in part by the
successful bone marrow homing and engraft, for which our data demonstrate a
key role for CD82. As such, we propose a model whereby CD82 serves to
modulate the activation of Rac1, which significantly impacts the migration,
adhesion and bone marrow homing behaviors of HSPCs. Finally, our detailed
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insight into how CD82 contributes to the homing and engraftment of HSPCs
implicates CD82 as an attractive therapeutic target to enhance the efficacy of
HSPC transplantation therapies.

2.5 Materials and methods
2.5.1 Mice
C57BL/6 wild-type and B6.SJL-Ptprca Pepcb/BoyJ mice were obtained from
Jackson Laboratory. CD45.1/CD45.2 chimeric mice were generated by mating
C57BL/6 and B6.SJL-Ptprca Pepcb/BoyJ mice. CD82KO mice were generated
from cre-loxP recombination (Wei et al., 2014). All experimental procedures were
approved by the Institutional Animal Care and Use Committee (IACUC) of the
University of New Mexico Health Science Center. Mice were housed under
pathogen-free conditions in the UNM Animal Facility. The age and sex of mice
were matched for each experiment.

2.5.2 Isolation and analysis of bone marrow cells
Bone marrow cells were isolated from the front and back limb bones using a
mortar and pestle. Isolated bone marrow cells were passed through a 40µM
strainer to remove bone fragments. Red blood cells were lysed using ACK lysis
Buffer (150mM NH4Cl, 10mM KHCO3, 0.1mM EDTA).

To assess HSC

populations, terminally differentiated cells were removed using a Lineage Cell
Depletion Kit (Miltenyi Biotec). Isolated Lin- cells were treated with Fc block
(2.4G2; BD Pharmingen) prior to surface marker staining. Isolated Lin- cells were
stained with antibodies against surface markers using the following antibodies:
mouse APC lineage cocktail (BD Pharmingen), BV605 CD117 (2B8; BD
Pharmingen) Pe-Cy7 Sca-1 (D7; BD Bioscience), FITC CD34 (RAM34; BD
Pharmingen), BV421 CD135 (A2F10.1; BD Pharmingen), BV510 CD48 (HM48-1;
BD Pharmingen) and PE CD150 (Q38-480; BD Pharmingen). Labeled bone
marrow samples were analyzed using the LSR Fortessa (BD Bioscience). For the
sorting of the HSPC population, the mouse HSC isolation kit (BD Pharmingen)
was used. Labeled cells were fluorescence activated cell sorted (FACS) using
the iCyt Sony sy32000 Sorter to obtain the Lin-Sca-1+c-kit+ (LSK) population. In
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addition, bone marrow immune cells were assessed using the following
antibodies: PerCP-Cy5.5 CD3 (145-2C11; BD Pharmingen), BV421 B220 (RA36B2; Biolegend), Pe-Cy7 Ly6G (IA8; BD Pharmingen) and Pe-Cy7 CD11b
(MI/70; BD Pharmingen). Labeled bone marrow samples were analyzed using
the LSR Fortessa (BD Bioscience).

2.5.3 Non-competitive and competitive repopulation assay
For non-competitive repopulation assay, 1X106 donor Lin- bone marrow cells
from CD82KO or WT (CD45.2) were retro-orbitally into recipient BoyJ mice
(CD45.1). For a competitive repopulation assay, 1X106 donor Lin- bone marrow
cells from CD82KO (CD45.2) and BoyJ (CD45.1) were retro-orbitally injected into
recipient chimeric mice (CD45.1/CD45.2). Recipient mice underwent a total body
irradiation, which was administered as a single dose of 10 gy. Each month blood
was taken from tail snips to assess chimerism and immune cell differentiation.
Cells were treated with Fc block prior to staining with the following directly
conjugated fluorescent antibodies: FITC CD45.1 (A20; BD Pharmingen) APC
CD45.2 (104; BD Pharmingen) PerCP-Cy5.5 CD3 (145-2C11; BD Pharmingen),
BV421 B220 (RA3-6B2; Biolegend), Pe-Cy7 Ly6G (IA8; BD Pharmingen) and
Pe-Cy7 CD11b (MI/70; BD Pharmingen). Labeled blood samples were analyzed
using the LSR Fortessa (BD Bioscience).

2.5.4 Cell cycle analysis
Lineage depleted bone marrow cells were incubated with Hoechst 33342 (SigmaAldrich) then labeled with PE Ki67 (16A8; BD Bioscience) in addition to LT-HSC
surface markers: Lineage, Sca-1, CD117, CD135, CD34, CD48 and CD150.
Cells were analyzed on the LSR Fortessa (BD Bioscience). For in vivo BrdU
incorporation studies, one dose of 1 mg BrdU (5-bromo-2-deoxyuridine; SigmaAldrich) was intraperitoneally injected into mice and bone marrow was collected 3
days later. Bone marrow samples were processed using the FITC BrdU Flow kit
(BD Bioscience) per the manufacturer’s instructions. Processed bone marrow
cells were labeled with surface markers: lineage, Sca-1, CD117, CD34, CD135
and CD150 to assess BrdU incorporation in the LT-HSC population. Cells were
analyzed on the LSR Fortessa (BD Bioscience).
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2.5.5 Non-competitive and competitive homing
For a non-competitive homing experiment, 1x106 donor bone marrow cells from
CD82KO or WT (CD45.2) were retro-orbitally injected into recipient chimeric mice
(CD45.1/CD45.2). For a competitive homing experiment, donor bone marrow
cells from CD82KO were mixed at a ratio of 1:1 with BoyJ competition bone
marrow cells into chimeric recipient mice. Competitive homing experiments were
also performed using isolated HSPCs from the bone marrow as described above.
Recipient mice underwent a total body irradiation, which was administered as a
single dose of 10gy. Mice were euthanized 16 hours post injection to assess
chimerism of the bone marrow and peripheral blood. Blood and bone marrow
samples were treated with Fc block prior to labeling with directly conjugated
fluorescent antibodies, FITC CD45.1 (A20; BD Pharmingen) and APC CD45.2
(104; BD Pharmingen) to assess chimerism. Samples were analyzed on the LSR
Fortessa (BD Bioscience).

2.5.6 Cell surface expression
Bone marrow cells were analyzed for the surface expression of PE CXCR4
(L276F12; Biolegend), PE β1 integrin (HM B1-1; BD Pharmingen), PE α4 integrin
(9C10; BD Pharmingen), PE-α6 integrin (GoH3; BD Pharmingen) and PE-CD44
(IM7; BD Pharmingen) on the LSK population. In addition, we also assessed
Rac-1 (Cytoskeleton) surface expression. Isolated bone marrow cells were
treated with Fc block prior to staining with the LSK markers. All samples were
labeled in MACs Buffer (PBS, 0.5% BSA, 2mM EDTA, pH 7.2; Miltenyi Biotec) for
30 min on ice. Samples were washed three times with MACs buffer after staining
and analyzed using the LSR Foretessa (BD Bioscience). Histograms were
created using FlowJo software.

2.5.7 Phosphoflow cytometry
Basal signaling activity was assessed by fixing isolated bone marrow cells with
4% Paraformaldehyde and permeabilizing with 100% methanol. Tonic signaling
activity was assessed by serum starving bone marrow cells in SFEM for 1hr at
37°. Starved cells were then fixed and permeabilized. After 1hr of serum
starvation, bone marrow cells were also treated with 100ng/mL SDF-1 for 2, 5, 10
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and 15 minutes. After each time point, samples were fixed and permeabilized.
Permeabilized samples were stained for LSK markers and the following signaling
molecules: p-AKT Pacific Blue (BD Pharmingen), p-ERK FITC (Biolegend), and
MEK2 PE (BD Pharmingen). Samples were analyzed on the LSR Fortessa (BD
Bioscience). The ratio of SDF-1 treatment was calculated by dividing Tonic mean
fluorescence intensity (MFI) by SDF-1 treatment MFI.

2.5.8 HSPC migration
The 4-chamber coverslips (Thermo Scientific) were coated with fibronectin
(50µg/mL in PBS; Millipore). Isolated HSPCs were plated at 250,000 cells/well on
fibronectin in StemSpanTM SFEM (StemCell Technologies) media supplemented
with murine cytokines: IL-3, SCF and FLT-3 (20ng/mL; Peprotech) overnight at
37°C. For EHOP-016 treatment, isolated HSPCs were treated with 5µM EHOP016 for 1hr at 37°C prior to plating. Each well was washed twice with PBS to
remove non-adherent cells. CO2 independent media supplemented with 0.5%
FBS was added to each well for 1hr and migration was measured using a Zeiss
Axiovert confocal microscope. Images were taken every 10 seconds for 50 min
and were analyzed using the ImarisTrack Software (Bitplane Oxford Instruments
Co.) to measure track length, track displacement and speed. The single cell
trajectory rose-plots were produced from track position parameter data generated
from the Imaris Tracking Software. The beginning X, Y position and ending X, Y
position of each HSPC was taken into account. Using the position data of each
HSPC, each track was normalized to shift each HSPC to an origin of (0,0). A total
of 15 positions between the beginning and end positions were randomly selected
in order to produce a track. For each condition, a total of 10 HSPCs were
assessed.

2.5.9 Cell spreading
The 8-chamber glass coverslips (Thermo Scientific) were coated with 50µg/mL of
fibronectin. Isolated HSPCs were placed in IMDM media supplemented with
10% FBS and plated at 200,000 cells/well on fibronectin for 1hr at 37°. For SDF1 treatment, cells were treated at 200ng/mL SDF-1 for 10 min. Medium was
removed from each well and washed three times. Adherent cells were fixed with
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4% PFA for 15min at room temperature. Each well was washed three times and
then blocked with 5% BSA in PBS for 30min at room temperature. Cells were
stained with rhodamine phalloidin F-actin stain (Invitrogen) for 1hr at room
temperature. Each well was washed out three times and replaced with PBS to
image. Cells were imaged using the confocal microscope using the LSM 510
software. Cell spreading was analyzed ImageJ software to measure the area of
each cell.

2.5.10 Western blot analysis
Total bone marrow was isolated from WT and CD82KO mice. Cells were lysed
in RIPA buffer containing (150mM NaCl, 0.1% SDS, 0.5% DoC, 50mM Tris pH
8.0 and 1% IGEPAL-NP40). Cell lysates were run on SDS-polyacrylamide gels
and transferred to nitrocellulose membranes. The membranes were blotted with
a mouse monoclonal antibody against mouse Rac1. Blots were developed using
ECL (Thermo Scientific).

2.5.11 Quantitative RT-PCR
Total RNA was extracted from total bone marrow and FACS isolated LSKs using
the RNeasy Micro Kit (Qiagen). RNA samples were quantified using a Nanodrop
2000 (Thermo Scientific). cDNA was made using qScript cDNA synthesis kit
(Quanta Bioscience) and amplified using a MyCycle Thermocycler (Bio Rad).
Real time polymerase chain reaction was done using SYBR Green PCR Master
Mix (Applied Biosystems). Primers for target genes were designed using PrimerBLAST (NCBI). Primers sets for each gene: Rac1 (Forward: 5’-AGA GTA CAT
CCC CAC CGT CT-3’ and Reverse: 5’- CAT GTG TCT CCA ACT GTC TGC-3’)
and glyceraldehydes-3-phosphate dehydrogenase (GAPDH) (Forward: 5’-AAC
TTT GGC ATT GTG GAA GG-3′ and Reverse: 5’- ACA CAT TGG GGG TAG
GAA CA-3’) (Scoumanne et al., 2011). Target genes were amplified using the
AB75000 Fast Real Time PCR System (Applied Biosystems). The endogenous
control gene GAPDH was used to normalize each sample. The relative change in
gene expression was calculated using 2-∆∆CT algorithm.
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2.5.12 Rac1 activity
WT and CD82KO lineage negative bone marrow HSPCs were lysed for the G
protein linked immunosorbent assay. G-LISA Rac-1 Activation Assay Biochem
Kit (catalog no BK128; Cytoskeleton Inc.) was performed per the manufacturer’s
instructions. In addition, Rac1 GTP (New East Biosciences) was assessed via
flow cytometry. Lineage depleted bone marrow cells were fixed, permeabilized
and treated with Fc block prior to staining with Rac1 GTP antibody. All samples
were labeled in MACs Buffer for 30 min on ice. Samples were washed three
times with MACs buffer after staining and analyzed using the Accuri C6 (BD
Bioscience). Histograms were created using FlowJo software.

2.5.13 EHOP homing
Prior to injection, 1x106 donor bone marrow cells from CD82KO (CD45.2) or WT
(CD45.2) were treated with 5µM EHop-016 (Selleckchem) or 50µM NSC23766
(Cayman Chemical) in SFEM for 1hr at 37°C. Treated cells were then retroorbitally injected into BoyJ recipient (CD45.1) mice. Recipient mice underwent a
total body irradiation, which was administered as a single dose of 10gy. Mice
were euthanized 16 hours post injection to assess chimerism of the BM and
peripheral blood. Blood and bone marrow samples were treated with Fc block
prior to labeling with directly conjugated fluorescent antibodies, FITC CD45.1
(A20; BD Pharmingen) and APC CD45.2 (104; BD Pharmingen) to assess
chimerism. Samples were analyzed on the LSR Fortessa (BD Bioscience).

2.5.14 Statistical analysis
Statistical significance was calculated using a Student’s t-test for which
significance was labeled * p<0.05, **p<0.01,*** p<0.001, ****p<0.0001. One-Way
ANOVA was used to calculate significance of EHOP migration and Rac-1
inhibitor (EHOP and NSC23766) homing studies for which significance was
labeled *p<0.05. The annotation n.s. is for non-significance. All statistical
analyses were performed using GraphPad Prism 6 Software.
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3.1 Abstract
Hematopoietic stem and progenitor cell (HSPC) egress into the blood
occurs under normal physiological conditions and upon treatment with mobilizing
agents. The trafficking of HSPCs from the bone marrow into the blood, or
mobilization, is stimulated in the clinic to enable the isolation of HSPCs used for
transplantation therapies. In this present study, we identified the tetraspanin
CD82 as a novel regulator of HSPC mobilization. Using a global CD82 knock out
(CD82KO) mouse model, we measured enhanced mobilization of HSPCs within
CD82KO mice following AMD3100 treatment, which results from CD82KO in the
HSPCs specifically. Moreover, we found that CD82KO HSPCs have increased
surface expression of sphingosine 1-phosphate receptor (S1PR1) and altered
downstream signal transduction, including ERK and AKT. Using ImageStream
cytometry, we identified disrupted S1PR1 internalization in the CD82 deficient
HSPCs, suggesting that CD82 plays a critical role in S1PR1 regulation. We went
on to find that the combined use of AMD3100 and anti-CD82 treatments
enhanced HSPC mobilization in animal models. Together, these data provide
evidence that CD82 is an important regulator of HSPC mobilization and suggests
exploiting the CD82 scaffold as a therapeutic target to enhance stem cell
mobilization treatments.

3.2 Introduction
Hematopoietic stem cell transplantation is a routinely performed treatment
for

malignant

and

non-malignant

hematological

diseases.

Successful

transplantation depends on a combination of factors, which include the number
and fitness of transplanted hematopoietic stem and progenitor cells (HSPCs).
Under static and stress conditions, HSPCs are released into the vasculature from
the bone marrow, in a process termed mobilization. Transplantation therapies
take advantage of this normal mobilization process by using specific treatments
such as granulocyte-colony stimulating factor (G-CSF) to enhance the
mobilization response, thereby increasing the number of HSPCs available in the
blood for harvest. However, studies suggest that 5-25% of patients mobilize
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poorly with G-CSF alone (Jantunen et al., 2012; Pusic et al., 2008). As such,
identifying novel molecules and mechanisms that regulate HSPC mobilization is
crucial for the improvement of transplantation therapies.
HSPC mobilization is mediated by a variety of key molecules such as
chemokines, cytokines and proteolytic enzymes that promote egress into the
peripheral blood. In particular, the chemokine receptor, CXCR4, which is highly
expressed on the surface of HSPCs, facilitates bone marrow migration towards
the chemoattractant, CXCL12. The clinical drug AMD3100 and G-CSF both
target the CXCR4 receptor in order to induce mobilization (Broxmeyer et al.,
2005; Uy et al., 2008). In addition to the CXCR4/CXCL12 signaling axis, the
lysophospholipid Sphingosine-1-phosphate (S1P) ligand produced by mature red
blood cells and activated platelets is found in high concentration within the
vasculature (Schwab et al., 2005). S1P binds to the Sphingosine-1-Phosphate
Receptors (S1PR1-5), which are G-coupled protein receptors (GPCRs) that elicit
downstream cellular activities such as migration, proliferation and cytoskeletal
rearrangement (Bendall and Basnett, 2013; Blaho and Hla, 2014). In particular,
the S1PR1 was shown to mediate HSPC mobilization in combination with
CXCL12 release from the bone marrow (Golan et al., 2012). Moreover, the
mobilization of HSPCs was identified to be dependent on the induction of S1PR1
towards a high S1P gradient within the blood and lymph. Together, these data
suggest an important role for S1PR1 in HSPC mobilization.
Previous work from our lab identified the tetraspanin CD82 as an critical
regulator of HSPC migration and adhesion within the bone marrow niche (SaitoReis et al., 2018). The tetraspanin family of scaffold proteins mediates a variety
of cellular processes such as cell migration, adhesion and signaling via their
regulation of surface molecules, including GPCRs, adhesion receptors and
receptor tyrosine kinases (Termini and Gillette, 2017). However, the specific
contribution of CD82 to HSPC mobilization had not been explored. Using a global
CD82 knock out (CD82KO) mouse model, we find that CD82 regulates HSPC
mobilization

through

the

regulation

of

S1PR1 expression

and

activity.

Furthermore, our data indicate that antibody targeting of CD82 promotes the
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mobilization of HSPCs, suggesting that CD82 may be a novel target to enhance
the release of HSPCs for improved transplantation therapies.

3.3 Results
3.3.1 Enhanced mobilization potential of CD82KO HSPCs.
To determine how the CD82 scaffold impacts HSPC mobilization, we
utilized the CD82KO mouse previously described (Jones et al., 2016; Wei et al.,
2014). Wild type (WT) and CD82KO mice were injected with AMD3100, a drug
used clinically to mobilize HSPCs, or a vehicle control. One hour after injection,
blood was harvested from the animals and the Lin-Sca1+Kit+ (LSK) HSPC
population was identified by flow cytometry. Under control treatment, a minimal
number of HSPCs were detected in the blood, with no difference identified
between WT and CD82KO animals (Figure 1A). As expected, AMD3100
treatment significantly increased the amount of mobilized HSPCs measured in
the blood, however an even greater increase in HSPC mobilization was detected
in the CD82KO mice when compared to WT (Figure 1A). In addition, colony
forming unit (CFU) assays were performed with the blood collected from WT and
CD82KO mice treated with AMD3100. Similar to the flow cytometry analysis,
AMD3100 treatment increased the number of CFUs measured in the CD82KO
mice when compared to WT (Figure 1B), further confirming an increased
mobilization potential of CD82KO HSPCs.
Since we are using a global CD82KO mouse model, we next wanted to
confirm that the enhanced mobilization we observe is due to the loss of CD82 on
the HSPCs rather than an effect of CD82KO within the bone marrow
microenvironment. Thus, we completed bone marrow transplants of WT or
CD82KO HSPCs into lethally irradiated B6.SJL-Ptprca Pepcb/BoyJ (CD45.1)
recipient mice. BoyJ mice maintain CD82 expression in all cells but carry the
differential pan leukocyte marker CD45.1, and thus, can be distinguished from
the WT and CD82KO donor cell populations that express the CD45.2 allele. The
bone marrow transplants were allowed to establish for two months and then both
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Figure 3.1: CD82KO HSPCs display enhanced mobilization.
(A) Flow cytometry analysis of %LSK (HSPCs) in peripheral blood collected from
WT and CD82KO micetreated with control PBS or AMD3100 (n=12-15
mice/group). ***p<0.001, **p<0.01, *p<0.05, two-way ANOVA. (B) Peripheral
blood CFU after AMD3100 induced HSPC mobilization (n=3 mice/group, in
triplicate. *p<0.05, unpaired t-test. (C) Flow cytometry analysis of %LSK in
peripheral blood collected after AMD3100 induced HSPC mobilization of WT and
CD82KO transplanted mice. (n=16-19 mice/group). *p<0.05, unpaired t-test.
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WT and CD82KO transplanted mice were treated with AMD3100 to induce
mobilization. Again, we used flow cytometry to quantify the LSK cells released
into the blood. Similar to our previous observation, we detect an increased
mobilization of transplanted CD82KO HSPCs when compared to WT cells,
indicating a cell-intrinsic defect of the CD82KO HSPCs (Figure 1C). Taken
together, these data suggest the loss of CD82 enhances HSPC mobilization and
implicates the CD82 scaffold as a regulator of HSPC egress.

3.3.2 CD82 regulates S1PR expression and signaling
HSPC mobilization is critically dependent upon S1PR signaling in
response to the S1P ligand gradient (Liu et al., 2011a; Schwab et al., 2005). S1P
is found at higher concentrations within the blood and thus can promote the
egress of HSPCs from the bone marrow (Liu et al., 2011a). We quantified the
S1P ligand within the plasma of WT and CD82KO mice under control and
AMD3100 treatment conditions, identifying no significant difference in S1P ligand
(Figure 2A). Next, we asked whether CD82 regulates HSPC egress by
modulating S1PR expression. Using flow cytometry, we characterized the
surface expression of the S1PR family, which consists of five receptors, S1PR1-5.
While we detected no difference in the surface expression of S1PR2, S1PR3, or
S1PR5 between WT and CD82KO HSPCs, we measured a significant increase in
the surface expression of S1PR1 and a more modest increase of S1PR4 in the
CD82KO HSPCs (Figure 2B). Since trafficking of HSPCS and their egress from
extramedullary tissues was shown previously to depend on S1PR1 expression
(Massberg et al., 2007; Ratajczak et al., 2010; Seitz et al., 2005), we set out to
determine if the increased expression of S1PR1 mediates the increased
mobilization of CD82KO HSPCs. The S1PR agonist, FTY720, can act upon
S1PR1-5, but it has the highest affinity for S1PR1 and stimulates the downregulation of the receptor. Therefore, we repeated the AMD3100 mobilization
experiments in the presence of FTY720, which results in the internalization of
S1PR1. As indicated in Figure 1, AMD3100 treatment of animals increased the
number of mobilized CD82KO HSPCs when compared to WT. However, upon
FTY720 treatment, the number of mobilized WT and CD82KO HSPC is
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Figure 3.2. CD82KO HSPCs have increased S1PR1 expression and
signaling. (A) S1P ligand plasma levels of WT and CD82KO plasma post PBS
control or AMD3100 treatment (n=3-4 mice/group). (B) Flow cytometry analysis
measured the mean fluorescence intensity (MFI) of WT and CD82KO HSPC
S1PR1-5 surface expression (n=4 mice/group). **p<0.01 and *p<0.05, unpaired ttest. (C) Flow cytometry analysis of %LSK in peripheral blood collected from WT
and CD82KO mice treated with AMD3100 or AMD3100/FTY-720 (n=6-8
mice/group). ***p<0.001, **p<0.01, n.s., non-significant, two-way ANOVA.
Phosphoflow cytometry analysisof (D) basal and (E) tonic (1hr serum starvation)
conditions to assess mean fluorescence intensity (MFI) of pAKT and pERK
signaling of the LSK population. (n=3-4 mice/group) ***p<0.001, unpaired t-test.
Phosphoflow cytometry analysis of 10µM S1P treatment at various time points
post 1hr serum starvation to assess (F) pAKT and (G) pERK signaling of the LSK
population. Quantification ratio calculated by dividing tonic signaling by S1P
treatment conditions (n=3-4 mice/group) ***p<0.001, **p<0.01, *p<0.05, unpaired
t-test
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decreased compared to AMD3100 treatment with no difference in mobilization
detected between WT and CD82KO mice (Figure 2C). Therefore the increased
mobilization of CD82KO HSPC is inhibited by downregulation of the S1PR1,
suggesting that the increased S1PR1 expression on CD82KO HSPCs mediates
the enhanced blood mobilization.
In addition to measuring an increase in S1PR1 and S1PR4 expression, we
also evaluated the downstream signal transduction from S1P ligand activation.
S1PR1 activates multiple intracellular signaling cascades, including the
extracellular signal-regulated kinase (ERK) and the phosphatidylinositol-3-linase
(PI3K)-AKT Pathways (Rosen et al., 2009). Using flow cytometry to perform
phosphoflow of pERK and pAKT, we detect a significant increase in basal levels
of pERK in CD82KO HSPCs when compared to WT, with no change in pAKT
(Figure 2D). We also serum starved the LSK population to measure the tonic
levels of pERK and pAKT expression between WT and CD82KO HSPCs,
identifying no difference (Figure 2E). However, following S1P stimulation, we
detected a significant increase in pERK expression in CD82KO HSPCs at early
time points (2, 10, and 20 min), which returned to WT levels at 30 min (Figure
2F) and a similar increase in pAKT levels in CD82KO HSPCs at slightly later time
points (10, 20 and 30 min) that returned to WT levels after 45 min (Figure 2G).
Collectively, these data suggest that in addition to increased S1PR1 expression,
CD82KO HSPCs also demonstrate enhanced signal transduction downstream of
ligand engagement.

3.3.3 CD82 regulates S1PR1 internalization
We next wanted to define how CD82 regulates S1PR1 expression and
signaling. Recognizing that tetraspanins including CD82 have been reported to
modulate

receptor

internalization,

we

examined

internalization

using

ImageStream cytometry. This technique combines flow cytometry with
fluorescence microscopy, enabling image-based analysis of large numbers of
cells per sample. Bone marrow was isolated from both WT and CD82KO animals
and antibody labeled for the S1PR1 at 4ºC to minimize endocytosis. Cells were
then moved to 37ºC and fixed at various time points to monitor S1PR1 trafficking.
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Figure 3.3: CD82KO HSPCs have decreased S1PR1 internalization.
Amnis Image flow cytometry analysis of % internalization of S1PR1 on WT and
CD82KO HSPCs during A) basal and (D) 10µM S1P treatment at various time
points. ****P<0.0001, Two-Way ANOVA. Representative images of S1PR1
internalization of WT and CD82KO HSPCs under (B,C) basal and (E,F) 10µM
S1P treatment at various time points.
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Cells were also antibody labeled with Lin+ antibodies so that the Lin- HSPC
population of cells could be identified by the ImageStream. Using the
internalization feature, we distinguished Lin- cells with surface labeled S1PR1
expression from those S1PR1 receptors that had been internalized over the
course of the 30 minute experiment. Under basal conditions, we find that
CD82KO HSPCs have decreased S1PR1 internalization compared to WT cells at
times 10, 20 and 30 minutes (Figure 3A-C). These data suggest that the
increased S1PR1 surface expression and enhanced signaling measured in
CD82KO HSPCs (Figure 2) is due at least in part to decreased S1PR1
internalization. Additionally, we assessed S1PR1 internalization upon S1P ligand
treatment using a relatively high concentration of S1P (10µM). Interestingly, upon
ligand treatment, we detected increased S1PR1 internalization of CD82KO
HSPCs compared to WT at time points 10, 20 and 30 minutes (Figure 3D-F).
These findings suggest that distinct pathways may be in place to regulate the
internalization of S1PR1 with CD82 promoting endocytosis under basal signaling
and perhaps attenuating internalization upon high concentrations of ligand.

3.3.4 Anti-CD82 treatment enhances HSPC mobilization
The observation that HSPCs are more readily released into the peripheral
circulation of CD82KO mice led us to ask whether CD82 could be a novel target
to promote HSPC mobilization. Previous studies have used antibodies to
illustrate a critical role for specific integrins in HSPCS mobilization (Bonig et al.,
2009; Craddock et al., 1997; Papayannopoulou et al., 1995; Papayannopoulou et
al., 1998; Papayannopoulou et al., 2001b). As such, we set out to determine if
pretreatment with anti-CD82 could induce HSPC mobilization in mice. WT mice
were intravenously injected with either 2mg/kg of anti-CD82 (M35) (Custer et al.,
2006) or control IgG for two hours and then treated with AMD3100 for 1 hour.
Blood was isolated and analyzed by flow cytometry to measure potential changes
in the population of peripheral blood mobilized HSPCs. While anti-CD82 alone
shows no effect on white blood cell (WBC) or HSPC mobilization, Figure 4
illustrates that mice treated with anti-CD82 in combination with AMD3100 display
increased WBC (Figure 4A) and LSK (Figure 4B) cell mobilization when
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Figure 3.4. CD82 Ab treatment enhances HSPC mobilization.
(A) Counts of white blood cells within the peripheral blood of WT mice treated
with IgG control or CD82 Ab upon PBS or AMD3100 treatment (n=4-5
mice/group). ***p<0.001 or *p<0.05, two-way ANOVA. (B) Flow cytometry
analysis of %LSK in peripheral blood collected from WT mice treated with IgG
control or CD82 Ab (n=4-5 mice/group). *p<0.05, two-way ANOVA. (C) Current
model illustrates the stem cell niche, which consists of the bone marrow and the
vasculature. This model depicts increased S1PR1 mediated CD82KO HSPCs
mobilization upon AMD3100 treatment. In addition, AMD3100+ CD82 antibody
treatment increased HSPC mobilization of WT HSPCs compared to IgG control
treatment.
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compared to controls. Therefore, anti-CD82 treatment stimulates an additive
mobilization of HSPCs when used in combination with AMD3100 and further
suggests that CD82 is a key contributor to the bone marrow retention of HSPCs.
Collectively, from these data we suggest the current model (Figure 4C) where the
CD82 scaffold regulates S1PR1 internalization, resulting in enhanced S1PR1
surface expression, signaling and increased HSPC mobilization.

3.4 Discussion
Decreased numbers of HSPCs harvested from the peripheral blood limits
the success of bone marrow transplantations. In fact, standard methods for
peripheral blood mobilization of hematopoietic stem cells fail to collect sufficient
stem cells in 5-40% of patients (Giralt et al., 2014). Therefore, identifying unique
targets to promote HSPC mobilization and increase HSPC numbers within the
peripheral blood is crucial for treatment of both non-hematological and
hematological malignancies. The tetraspanin family of scaffold proteins function
as molecular facilitators interacting with adhesion and signaling molecules at the
plasma membrane to create tetraspanin-enriched microdomains (TEMs) (Charrin
et al., 2009; van Deventer et al., 2017). TEMs contribute to a number of cellular
functions, including migration, adhesion and protein trafficking (Termini and
Gillette, 2017; van Deventer et al., 2017). Specifically within HSPCs, tetraspanins
are described to impact homing, engraftment, migration, and quiescence (Charrin
et al., 2009; Hur et al., 2016; Larochelle et al., 2012; Marjon et al., 2016; SaitoReis et al., 2018), and in the current study, we identified a novel role for the
tetraspanin CD82 as a critical regulator of HSPC mobilization.
Under normal physiological conditions, HSPCs are found in circulation at
very low numbers (Massberg et al., 2007). However, increased numbers of
HSPCs mobilize into the blood in response to injury, infection or stress (Heidt et
al., 2014; Massberg et al., 2007). Additionally, treatments such as GCSF and
Plerixafor (AMD3100), which target CXCR4, are used to induce peripheral blood
mobilization of HSPCs for stem cell transplant. Using the well characterized
CD82KO mice (Jones et al., 2016; Saito-Reis et al., 2018; Wei et al., 2014), we
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identified an increase in the mobilization capacity of HSPCs from CD82KO mice
following AMD3100 treatment. Through a combination of transplant experiments,
we went on to show that CD82KO, specifically within the HSPC population, is
primarily responsible for the enhanced mobilization phenotype. Previous work
from our lab thoroughly evaluated the expression and signaling potential of the
CXCR4 receptor in the context of the CD82KO HSPCs, finding no altered
expression or signaling of CXCR4 (Saito-Reis et al., 2018). Therefore, despite its
essential role in regulating bone marrow interactions, these data suggest that
CXCR4 is unlikely to be a key contributor to the observed mobilization defect.
Additionally, our previous work analyzed the integrin profile of CD82KO HSPCs,
including the integrin α4β1 (Saito-Reis et al., 2018), which also impact the bone
marrow retention of HSPCs. Our findings identified no difference in α4 integrin
expression and a minor decrease in β1 integrin expression in CD82KO HSPCs
(Saito-Reis et al., 2018), which suggests a modest potential for integrin
involvement in CD82-mediated mobilization. These collective data led us to
evaluate the role of the S1P receptor class of GPCRs.
S1P receptors are targets of the lipid signaling molecule S1P, which
facilitates the egress of HSPCs from the bone marrow into the blood (Ratajczak
et al., 2010; Rosen et al., 2009; Schwab et al., 2005; Seitz et al., 2005). S1P
stimulates multiple cellular processes including proliferation, stress fiber
formation and migration. Within the receptor family, the S1PR1 is the most well
characterized as an important mediator of HSPC mobilization (Golan et al., 2012;
Liu et al., 2011a; Ratajczak et al., 2010; Schwab et al., 2005). Previous work
found that treatment of mice with the S1PR1 agonist, FTY-720, results in the
rapid downregulation and degradation of the receptor and subsequently prevents
HSPC mobilization (Mullershausen et al., 2009). Our data suggest that CD82KO
HSPCs have an increased mobilization capacity, due at least in part to S1PR1,
since treatment of CD82KO mice with FTY-720 ablated the enhanced
mobilization observed in these animals. Further analysis of the CD82KO HSPCs
identified increased surface expression of S1PR1 when compared to WT cells,
suggesting that the enhanced mobilization is promoted by an increase in S1PR1
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surface expression. One potential mechanism for the increase in S1PR1 surface
expression is through disruptions in receptor internalization. For example, the
tetraspanin CD63 was shown to mediate receptor internalization of the H,KATPase β-subunit through direct interaction (Duffield et al., 2003). Additionally,
CD82 was identified to regulate epidermal growth factor receptor (EGFR)
endocytosis through TI-VAMP expression (Danglot et al., 2010). Moreover, work
from our own lab identified a role for CD82 in the regulation of internalization and
recycling of the α4 integrin (Termini et al., 2014). Previous studies identified a
role for dynamin-2 (Willinger et al., 2014) and the clathrin-mediated endocytic
pathway (Reeves et al., 2016) in the uptake of S1PR1. Our current data also
implicates CD82 to be involved in the regulation of S1PR1 internalization.
Interestingly, we find that in contrast to the decreased S1PR1 internalization
observed under based conditions in the CD82KO HSPCs, we find that S1PR1
internalization is enhanced upon S1P treatment. These findings suggest that
distinct pathways may be in place to regulate the internalization of S1PR1. The
crystal structure of S1PR1 provides insight into the location of the ligand pocket
that is restricted between helices VII and I within the transmembrane region
(Hanson et al., 2012). This study also went on to show that the N-terminal tail of
S1PR1 folds over the top of the receptor to block access to the ligand binding
pocket, suggesting that ligand access to the binding pocket occurs from within
the cell membrane and not the extracellular space. As such, CD82 and the TEMs
that it assembles may have a unique ability to modulate ligand access to S1PR1,
which could also contribute to the increased S1PR1 endocytosis observed in
CD82KO HSPCs following S1P treatment. Whether CD82 interacts directly or
indirectly with S1PR1 still remains unclear.
PI3K/AKT and ERK are known signaling pathways stimulated downstream
of S1PR1 activation (Rosen et al., 2009). Using phosphoflow cytometry analysis,
we demonstrated that upon S1P ligand binding, CD82KO HSPCs have increased
pERK and pAKT signaling when compared to WT HSPCs. The increased S1PR1
expression observed on the CD82KO HSPCs is likely a primary contributor to the
increased activation of ERK and AKT detected. However, the tetraspanin scaffold
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has also been described as a mechanism to modulate signaling directly at the
plasma membrane (Termini and Gillette, 2017). In fact work from our own lab
demonstrated that CD82 can stabilize PKCα at the plasma membrane, promoting
the sustained downstream signaling of MAPK and ERK1/2 in acute myeloid
leukemia cells (Termini et al., 2016). In addition to ERK and AKT signaling, PKCα
and Rac1 GTPase activation have been described to signal downstream of
S1PR1. Interestingly, both PKCα and Rac1 were previously described to be
modulated by the CD82 scaffold (Saito-Reis et al., 2018; Termini et al., 2016).
Therefore, future studies will be required to help identify the mechanisms by
which CD82 influences S1PR1 signaling and the impact on specific downstream
pathways.
Hematopoietic stem cell transplantations often fail due to insufficient
numbers of harvested HSPCs (Copelan, 2006; Hatzimichael and Tuthill, 2010).
Under normal physiological levels, HSPCs circulate at 0.04% within the blood
(Massberg et al., 2007). Currently, within the clinic mobilizing agents are often
used for harvesting HSPCs in lieu of the alternative invasive method such as
bone

marrow

aspiration

(Hatzimichael

and

Tuthill,

2010).

Therefore,

understanding the mechanisms and molecules that facilitate HSPC mobilization
is critical to increase HSPCs within the blood for transplantation. Previous work
has shown that HSPC mobilization can be induced through the use of antibodies.
For example, intravenous treatment with antibodies targeting the integrin α4
resulted in enhanced HSPC mobilization (Bonig et al., 2009; Qian et al., 2006).
Additionally, another study used a CD82 monoclonal antibody to mobilize AML
cells into the peripheral blood, which led to increased effects of chemotherapy
treatment (Nishioka et al., 2015). In this study, we demonstrate that intravenous
injection of a CD82 antibody into WT mice increased HSPC mobilization, further
strengthening the critical role for CD82 in HSPC mobilization. At this time, how
the antibody impacts TEMs and specifically S1PR1 signaling remains unclear.
When taken together, our data provide evidence for CD82 to be used as a novel
target in the clinic to mobilize HSPCs for transplantation therapies.
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3.5 Materials and Methods
3.5.1 Mice
C57BL/6 wild-type and B6.SJL-Ptprca Pepcb/BoyJ mice were obtained from
Jackson Laboratory. CD82KO mice were generated from cre-loxP recombination
(Wei et al., 2014). All experimental procedures were approved by the Institutional
Animal Care and Use Committee (IACUC) of the University of New Mexico
Health Science Center. Mice were housed under pathogen-free conditions in the
UNM Animal Facility. The age and sex of mice were matched for each
experiment.

3.5.2 HSPC Mobilization
Mice were subcutaneously injected with one dose of 5mg/kg AMD3100 (Sigma
Aldrich). Control treated mice were subcutaneously injected with PBS. Peripheral
blood was collected by a cardiac puncture 1hr post AMD3100 injection. The
inhibitor for S1PR, FTY720 (Cayman Chemicals) was injected i.p. at 10mg/kg 14
hours before AMD3100 treatment. The inhibitor for the S1P lyase, 4deoxypyridoxine (DOP) (Cayman Chemicals) was supplemented into the drinking
water for 3 days at 30mg/L with 10g/L glucose. RBCs were lysed using ACK lysis
buffer. The amount of mobilized HSPCs within the blood were quantified using
the following directly conjugated fluorescent antibodies for mouse APC lineage
cocktail (BD Pharmingen), Pe-Cy7 Sca-1 (D7; Biolegend) and PE CD117 (2B8,
Biolegend). Labeled samples were then read on the LSR Fortessa (BD
Bioscience) to determine the percentage of HSPCs mobilized based off of the
total population.

3.5.3 Colony-forming assay
Peripheral blood collected from a cardiac puncture was collected 1hr post
treatment with either PBS or 5mg/kg AMD3100. RBCs were lysed using ACK
lysis buffer. Blood cells were plated at 100,000 cells/dish suspended in Isocove’s
Modified Dulbecco’s Medium (IMDM) media and placed in MethocultTMGF M3434
(StemCell Technologies). The total amount of colonies was scored 12 days later
using gridded scoring dishes (Stem Cell Technologies). Colonies were scored
using a Zeiss Axioskop microscope.
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3.5.4 Isolation and analysis of bone marrow cells
Bone marrow cells were isolated from the front and back limb bones using a
mortar and pestle. Isolated bone marrow cells were passed through a 40µM
strainer to remove bone fragments. Red blood cells were lysed using ACK lysis
Buffer (150mM NH4Cl, 10mM KHCO3, 0.1mM EDTA). Isolated bone marrow cells
were treated with Fc block (2.4G2; BD Pharmingen) prior to surface marker
staining. Bone marrow cells were stained with antibodies against the following
surface markers: mouse APC lineage cocktail (BD Pharmingen), Pe-Cy7 Sca-1
(D7; Biolegend) and PE CD117 (2B8, Biolegend). Labeled bone marrow samples
were analyzed using the LSR Fortessa (BD Bioscience) or Accuri C6 Flow
Cytometer (BD Bioscience).

3.5.5 HSPC engraftment mobilization
For engraftment assay, 1X106 donor Lin- bone marrow cells from CD82KO or WT
(CD45.2) were retro-orbitally into recipient BoyJ mice (CD45.1). Recipient mice
underwent a total body irradiation, which was administered as a single dose of 10
gy. One month post transplant, HSPCs were mobilized with a single dose of
5mg/kg AMD3100. Peripheral blood was collected by a cardiac puncture 1hr post
AMD3100 injection. The amount of HSPC within the blood was quantified using
the antibodies and procedure described in the “HSPC mobilization” section.

3.5.6 S1P Ligand ELISA
S1P ligand protein concentration from WT and CD82KO plasma were
determined

by

enzyme-linked

immunosorbent

assay

(ELISA)

(Echelon

Biosciences Inc) per the manufacturer’s instructions. Blood was collected from a
cardiac 1hr post control or ADM3100 treatment. Collected blood were allowed to
sit for 2hrs. Blood samples were centrifuged at 2.0 rcf for 20min to isolate
plasma. Plasma samples were then assessed using the S1P ELISA kit.

3.5.7 Cell surface expression
Bone marrow cells were analyzed for the surface expression of S1PR1 (R&D
Systems), S1PR2 (Proteintech), S1PR3 (Alomone Labs), S1PR4 (ThermoFisher
Scientific) and S1PR5 (Proteintech) on the HSPC population. All samples were
labeled in MACs Buffer (PBS, 0.5% BSA, 2mM EDTA, pH 7.2; Miltenyi Biotec) for
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30 min on ice. Samples were washed three times with MACs buffer after staining
and analyzed using the LSR Foretessa (BD Bioscience). Histograms were
created using FlowJo software.

3.5.8 Phosphoflow cytometry
Basal signaling activity was assessed by fixing isolated bone marrow cells with
4% Paraformaldehyde and permeabilizing with 100% methanol prior to antibody
staining. Tonic signaling activity was assessed by serum starving bone marrow
cells in SFEM for 1hr at 37°. Starved cells were then fixed and permeabilized.
After 1hr of serum starvation, bone marrow cells were also treated with 10uM
S1P for 2, 10, 20, 30, 45 and 60 minutes. After each time point, samples were
fixed and permeabilized. Permeabilized samples were stained for LSK markers
and the following signaling molecules: p-AKT Pacific Blue (BD Pharmingen), and
p-ERK Alexa 488 (Biolegend). Samples were analyzed on the LSR Fortessa (BD
Bioscience). The ratio of S1P treatment was calculated by dividing Tonic mean
fluorescence intensity (MFI) by S1P treatment MFI.

3.5.9 Internalization of S1PR1
Total bone marrow harvested from WT and CD82KO mice were labeled on ice
for 1 hour using S1PR1 (anti-EDG1 ab11424; Abcam). Cells were then labeled
using an Alexa 488 anti-rabbit secondary for 45 min. In addition, cells were
labeled with mouse APC anti-lineage cocktail (BD Bioscience). An aliquot of cells
were fixed with 4% PFA at time point 0, which is considered 100% surface
staining. Remaining cells were placed at 37° in the presence or absence of 10µM
S1P ligand (Caymen Chemicals) for 10, 20 and 30 minutes. At each time point
approximately 1x106 cells were removed and fixed. Samples were assessed on
the ImageStream multispectral imaging flow cytometer (Amnis) and data
collected were analyzed using the IDEAS image-analysis software (Amnis). For
each sample, 10,000 events were collected. Internalization was assessed on the
lineage negative population. The internalization feature was used to determine
the ratio of intensity inside the cell/intensity of the entire cell. The feature used to
define internalization is an adaptive erosion mask that fits within the membrane
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of the cell. Internalization is graphed by subtracting the internalization percentage
from each time point to time 0.

3.5.10 Statistical analysis
Statistical significance was calculated using a Student’s t-test for which
significance was labeled * p<0.05 and **p<0.01. Two-Way ANOVA was used to
calculate significance of Mobilization studies (Control and AMD3100) and
(AMD3100, AMD3100/FTY720, AMD3100/CD82Ab) for which significance was
labeled * p<0.05, **p<0.01, and *** p<0.001. The annotation n.s. is for nonsignificance. All statistical analyses were performed using GraphPad Prism 6
Software.
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Chapter 4: Conclusions, significance and future directions
4.1 Conclusions
The studies described in my dissertation provide novel information
regarding how tetraspanins regulate HSPC fitness and bone marrow retention.
Utilizing the global CD82KO mouse, we identified the tetraspanin CD82 as an
important regulator of HSPC quiescence, homing, engraftment and mobilization,
Figure 5.1.
In chapter 2, our data demonstrate that the loss of CD82 results in
decreased LT-HSCs within the bone marrow of mice, due to increased HSPC
cycling. In addition, we measured decreased competitive bone marrow
engraftment of CD82KO HSPCs, which we determined was in part due to
decreased HSPC homing. Ultimately, we found that the CD82KO HSPC bone
marrow homing defect was due to Rac1 hyperactivation, which we rescued with
Rac1 inhibitor treatment. Collectively, these data demonstrate an important role
for CD82 in HSPC quiescence, homing and engraftment.
In chapter 3, our data demonstrate that HSPCs from CD82KO mice have
enhanced mobilization from the bone marrow into the blood upon AMD3100
treatment. We determined that increased CD82KO HSPC mobilization is in part
due to increased S1PR1 surface expression. In addition, using image-based flow
cytometry, we found that CD82KO HSPCs have increased S1PR1 surface
expression due to decreased receptor internalization. Additionally, phosphoflow
studies with S1P ligand treatment demonstrated that CD82KO HSPCs have
increased pERK and pAKT signaling when compared to WT HSPCs. Moreover,
we found that anti-CD82 treatments further enhance HSPC mobilization into the
blood of mice. Therefore, these data demonstrate that CD82 regulates S1PR1mediated HSPC mobilization and suggests CD82 may serve as a therapeutic
target to promote HSPC egress.

4.2 Significance
Maintenance of LT-HSCs is critical to preserve the hematopoietic
population. The LT-HSC population is primarily kept in a quiescent state within
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Figure 5.1: Conclusion Model. The stem cell niche consists of the bone marrow
(also termed the endosteal niche) and vasculature. In Chapter 2 (shown in green)
we determined that CD82 is an important regulator of HSPC quiescence, homing
and engraftment. In this model, HSPCs are primarily found in the bone marrow
microenvironment in a quiescent state. Additionally, HSPCs home to the bone
marrow by extravasating through endothelial cells in order to enter the bone
marrow niche for engraftment. Our data suggest that the loss of CD82 leads to
decreased HSPC quiescence and a defect in HSPC homing and engraftment. In
chapter 3 (shown in blue) we determined that CD82 is an important regulator of
HSPC mobilization. In this model, HSPC mobilization occurs under normal
physiological conditions and upon treatment with chemotherapy or mobilizing
agents. Our data suggest that CD82KO HSPCs undergo enhanced mobilization
due to increased S1PR1 surface expression. Together these data provide
evidence that CD82 is a critical regulator of HSPC maintenance and function.
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the bone marrow microenvironment to prevent HSC exhaustion and ultimately
bone marrow failure (Kiel et al., 2007a; Pietras et al., 2011). Therefore,
understanding the key molecules involved in regulating HSC quiescence is
important especially for in vitro and ex vivo studies where the HSC pool is
expanded for stem cell transplants. However, the maintenance of HSCs in vitro
and ex vivo is problematic due to the loss of stem like and long-term
reconstitution properties, which in part is due to differentiation (Ko et al., 2017;
Ogawa et al., 1997; Schuster et al., 2012; Xie and Zhang, 2015). Regulation of
HSC quiescence occurs through a number of signaling pathways, which include
Notch, Wnt and TGFβ (Angers and Moon, 2009; Bigas and Espinosa, 2012;
Bigas et al., 2013; Hur et al., 2016; Kopan and Ilagan, 2009; Larochelle et al.,
2012). We and others have shown that CD82 is also an important modulator of
HSPC quiescence (Hur et al., 2016; Larochelle et al., 2012; Saito-Reis et al.,
2018). For example, CD82 expression on HSPCs has been shown to promote
interactions with adjacent cells within the bone marrow niche, which could
contribute to HSPC quiescence. More specifically, the contact site between
human CD34+ HSPCs and osteoblasts was shown to have increased CD82
expression and plasma membrane enrichment of CD82 occurred in the G0 phase
of the cell cycle (Larochelle et al., 2012). Using a global CD82KO mouse model,
my studies show that the CD82KO LT-HSC population is reduced in the bone
marrow compared to WT mice (Saito-Reis et al., 2018). Aligned with our findings,
Hur et al. also detected a significant decrease of LT-HSCs within the bone
marrow using a different CD82KO mouse, which further supports the conclusion
that CD82 is an important regulator of LT-HSC quiescence. However, Hur et al.
suggests that LT-HSC quiescence is maintained through an interaction with
DARC expressed on macrophages, which is controversial in the tetraspanin field
due to the lack of evidence that confirms this interaction. The interaction between
CD82 and DARC was first discovered using a yeast two-hybrid screen
(Zoughlami et al., 2012), however, in combination with non-specific mouse CD82
antibodies used in the Hur et al study, this interaction still needs to be validated.
Our studies went on to find that the loss of CD82KO LT-HSCs within the bone
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marrow is due to increased stem cell activation and cycling. Chronic HSC
activation often results in bone marrow failure (Baumgartner et al., 2018;
Harrison and Astle, 1982; Harrison et al., 1990; Mauch et al., 1988; Pawliuk et
al., 1996), which often leads to the need for bone marrow transplantation.
Therefore, my studies suggest that CD82 expression may be a potential marker
for bone marrow failure.
The fitness of HSPCs is critical for the successful reconstitution of the
hematopoietic system. We define HSPC fitness as the ability of HSPCs to
effectively home and engraft within the bone marrow of a lethally irradiated
organism. HSPC engraftment is essential to repopulate the hematopoietic cells of
an individual that has undergone chemotherapy or radiation treatment. My study
is significant because we identified a role for CD82 in HSPC engraftment. We
found that CD82KO HSPCs are able to effectively engraft into lethally irradiated
mice when transplanted on their own. In fact, monthly blood and immune cell
phenotype analysis of WT and CD82KO engrafted mice suggest CD82KO
HSPCs are functional with production of B, T and myeloid cells. However, we did
detect a significant defect when CD82KO HSPCs were transplanted in a
competitive repopulation assay with WT HSPCs. Here, we detected a decreased
amount of circulating CD82KO cells within recipient mice compared to WT cells,
which demonstrates a defect in CD82KO HSPC engraftment.

Moreover WT

derived T and B cells were measured in the blood, however, we detected
increased numbers of CD82KO-derived myeloid cells within the blood of
competitively engrafted recipient mice. The myeloid skewing we observed could
be due to an ageing phenotype of the CD82KO mice. Additionally, many studies
have shown that the loss of CD82 alters lymphoid cell activation and responses,
which could explain the decreased production of lymphoid cells detected within
the competitive repopulation assay. Many studies have described an important
role for CD82 as an important co-stimulatory receptor for T cell activation
(Delaguillaumie et al., 2004; Delaguillaumie et al., 2002; Iwata et al., 2002;
Lagaudriere-Gesbert et al., 1998; Lebel-Binay et al., 1995). Using the same
CD82KO mouse model, another group showed a dysregulation of T cell IFN-γ
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response (Jones et al., 2016). Moreover CD82 was shown to interact with the B
cell marker CD19 in a coimmunoprecipitation assay using B cell lines, but no
function has been described (Horvath et al., 1998). More studies will need to be
done to determine if the homing and engraftment defects we observed are due to
enhanced ageing of the CD82KO hematopoietic compartment, which is
consistent with the myeloid skewing we detect. Collectively these data suggest
that CD82 is important for the engraftment of HSPCs.
Efficient HSPC homing is the first step for successful HSPC bone marrow
engraftment. Understanding the molecules involved in HSPC homing is critical to
improving this process for successful engraftment of HSPCs into the bone
marrow microenvironment. We and others have determined a role for CD82 in
HSPC homing (Larochelle et al., 2012; Marjon et al., 2016; Saito-Reis et al.,
2018). One study demonstrated that human CD34+ HSPCs that were pre-treated
with a CD82 blocking antibody and then intravenously injected into NSG mice
showed decreased bone marrow homing (Larochelle et al., 2012). Also, previous
data from our lab showed that CD82 regulates bone marrow homing of AML cells
through the modulation of N-Cadherin (Marjon et al., 2016) and α4 integrin
(Termini et al., 2014) organization and expression. My study specifically
assessed a role for CD82 in HSPC homing. We demonstrate that CD82KO
HSPCs and total bone marrow have decreased bone marrow homing. In
addition, in vitro studies measured increased cell spreading and decreased
migration of CD82KO HSPCs. Protein analysis using GLISA and active Rac1specific antibodies measured an increase in active Rac1 in CD82KO HSPCs.
The increase in Rac1 activity could explain the increase in cell spreading
measured of CD82KO HSPCs plated on fibronectin and laminin. A specific study
showed increased cell spreading of CD82KO dendritic cells (Jones et al., 2016).
The increase in cell spreading we detect could also contribute to the decrease in
cell migration measured by in vitro migration studies. We were able to recover
CD82KO HSPC bone marrow homing and in vitro migration with the use of Rac1
inhibitors, EHOP and NSC23766. Therefore, our study suggests that regulation
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of Rac1 activity downstream of CD82 is critical for promoting successful HSPC
homing.
Under normal physiological conditions, HSPCs are found in circulation at
very low numbers (Massberg et al., 2007). However, increased numbers of
HSPCs mobilize into the blood in response to injury, infection or stress (Heidt et
al., 2014; Massberg et al., 2007). Our study is the first to describe a role for
CD82 in HSPC mobilization. In chapter 3, we determined that CD82 modulates
HSPC mobilization through the regulation of the S1PR1. The CXCR4 and S1PR1
receptors are heavily studied as important mediators of HSPC mobilization
(Golan et al., 2012; Juarez et al., 2012; Nie et al., 2008; Tzeng et al., 2011).
However, we found no difference in CXCR4 expression or activity as mentioned
in chapter 2, so we focused our attention on S1PR1.The loss of CD82 results in
enhanced HSPC mobilization through the increased surface expression of
S1PR1. We determined that increased S1PR1 surface expression on CD82KO
HSPCs is due to decreased internalization of this receptor. At this time, more
studies need to be conducted to determine if there is a direct or indirect
interaction between CD82 and S1PR1. Collectively, these studies present an
important role for CD82 in HSPC mobilization, which could be exploited to
improve the mechanisms for harvesting stem cells for bone marrow
transplantations.
4.2.1 Clinical Significance
Currently, HSPCs are the gold standard treatment in the clinic for nonhematologic and hematologic diseases (Copelan, 2006). Allogenic bone marrow
transplantation is the most common treatment method, which uses stem cells
from a donor (Copelan, 2006; Hatzimichael and Tuthill, 2010). The different
sources of hematopoietic stem cell collection are from bone marrow, peripheral
blood or cord blood. However, there are two major limitations of bone marrow
transplantations which include: 1) limited numbers of transplanted stem cells
effectively engraft into the bone marrow and 2) limited numbers of stem cells are
acquired at time of collection. Therefore, determining the molecules and

110

mechanisms involved in HSPC homing, engraftment and mobilization will
improve the efficacy of bone marrow transplants.
In chapter 2, we determined that CD82 is an important regulator of HSPC
bone marrow homing and engraftment. We found that in the absence of CD82,
HSPC bone marrow homing and engraftment is decreased. Therefore, in the
clinic CD82 could be used an additional marker to predict stem cell transplant
success. We hypothesize that increased CD82 expression would promote HSPC
bone marrow homing, therefore, resulting in successful transplantation.
According to the National Marrow Donor Program, from 1998 to 2011, the
amount of transplants performed using peripheral blood stem cell transplants
increased over time. Currently, collection of mobilized HSPCs within the
peripheral blood is preferred compared to the alternative bone marrow puncture.
Although current collection methods of mobilized HSPCs from the peripheral
blood yields less stem cells compared to other collection methods, this method
also allows for quicker donor recovery. Therefore, determining ways to improve
HSPC mobilization into the peripheral blood will increase the amount of HSPCs
for collection. In chapter 3, we determine that CD82 may be a novel target to
increase HSPC mobilization into the peripheral blood for the use of bone marrow
transplants. Many studies have shown that the use of antibodies to block surface
receptor/molecule expression can promote HSPC mobilization (Bonig et al.,
2009; Craddock et al., 1997; Nishioka et al., 2015; Papayannopoulou et al.,
1995; Papayannopoulou et al., 1998; Papayannopoulou et al., 2001b; Qian et al.,
2006). Additionally, our data in chapter 3 suggests that treatment of WT mice
with a CD82 antibody, in combination with AMD3100, promotes HSPC
mobilization compared to WT HSPCs. Therefore, these findings are promising
evidence that antibodies against CD82 can enhance HSPC mobilization.

4.3 Future directions
A few unanswered questions remain about the mechanism by which CD82
mediates HSPC quiescence. We found that CD82 is an important regulator of
HSPC quiescence, however, future studies are needed to determine what
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signaling pathways are altered to induce CD82KO HSPC activation. Potential
regulators of HSPC quiescence are the Notch and or Wnt signaling pathways,
which could be altered in CD82KO HSPCs to induce cycling (Angers and Moon,
2009; Bigas and Espinosa, 2012; Bigas et al., 2013; Kopan and Ilagan, 2009).
Hur et al. suggested that CD82KO HSPC activation is mediated by the TGFβ
signaling pathway. However, the induction of this pathway through the interaction
between CD82 and DARC is still controversial. Future experiments could
investigate if the Notch, Wnt or TGFβ signaling pathways are responsible for the
increased CD82KO HSPC activation that we observe. Therefore, identifying a
mechanism for CD82KO HSPC quiescence would be essential to maintain the
primitive HSC pool.
The interactions between HSPCs and the bone marrow microenvironment
are critical for the tight regulation of the hematopoietic compartment.
Tetraspanins are known to interact with other tetraspanins, adhesion and
signaling molecules to form tetraspanin-enriched micro-domains (TEMs). Our lab
showed that CD82 expression and organization on the surface of AML cells
modulates α4 integrin and N-Cadherin expression to promote HSPC and bone
marrow interactions (Marjon et al., 2016; Termini et al., 2014). In chapter 2, we
also identified a significant decrease in the α6 integrin surface expression on
CD82KO HSPCs, which could result in weaker interactions and allow for easier
activation of HSPCs within the bone marrow microenvironment. To investigate if
decreased expression of the α6 integrin of CD82KO HSPCs results in weak bone
marrow interactions, future experiments could include transduction of the α6 to
try and rescue integrin to rescue this phenotype. Collectively, these experiments
would identify a role for α6 in promoting CD82-mediated HSPC interactions with
the bone marrow.
Chronic stress has been shown to promote HSPC activation, which results
in pathological diseases such as bone marrow failure and more recently
cardiovascular diseases (Heidt et al., 2014). Our data suggest that CD82KO
HSPCs have increased activation under basal conditions, but downstream
pathologies have not yet been detected. We hypothesize that increased HSPC
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activation in CD82KO animals results in enhanced differentiation of inflammatory
immune cells, which could contribute to atherosclerotic plaque formation. My
preliminary studies show that CD82KO mice have increased aortic lipid content
compared to WT mice (Supplemental Figure 3). However, future studies are
needed to assess the mechanism for increased lipid content within the aortas of
CD82KO mice under basal conditions. Future studies could also assess the
pathogenic burden of the cardiovascular system within WT and CD82KO mice
placed on a high fat diet. Furthermore, measurements of circulating inflammatory
immune cells within the vasculature of WT and CD82KO mice on a normal chow
or high fat diet could offer insight into a mechanism for increased aortic lipid
content.
HSPCs undergo a series of self-renewal and differentiation processes that
are critical for the maintenance of the hematopoietic compartment. Classic signs
of HSPC aging include increased stem cell activation, decreased homing and
engraftment and myeloid skewing. Based on our studies, we have detected these
classic aging signs within CD82KO HSPCs. Determining the mechanism for
myeloid skewing of CD82KO HSPCs is of interest because we detect this
phenotype only under stress conditions (Fluorouracil (5-FU) treatment, serial
transplantation and competitive engraftment). We have conducted a serial
transplantation experiment in which we detected a significant decrease of the WT
pool at the tertiary engraftment, which is when we expected exhaustion of the
HSC pool (Supplemental Figure 1). However, at the tertiary and quartenary
engraftment we detected a significant increase in the CD82KO pool, which was
unexpected due to the increase in HSPC activation we measured in the CD82KO
mouse (Supplemental Figure 1). Furthermore, we went on to characterize the
immune cell populations from each donor pool and found that majority of the
CD82KO tertiary and quaternary population were from the myeloid lineage
(Supplemental Figure 2). This phenotype is consistent with myeloid skewing that
we have detected with the competitive repopulation experiments described in
chapter 2. Future experiments will be done to determine what could be
contributing to the myeloid skewing phenotype we detect and to see if we have a
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leukemic phenotype due to the hyperproliferation of myeloid cells. We have not
detected any oncogenic phenotype within the CD82KO mouse model under
normal physiological conditions However, we speculate that the deletion of exon
5 and 6 of CD82 within our mouse model could contribute to this oncogenic
phenotype. One study showed that a splice variant of CD82 due to the deletion of
exon 7 increased tumorgenicity and invasion of gastric cancer (Lee et al., 2003).
Therefore, future studies are needed to determine if the deletion of CD82 in our
KO mice can contribute to oncogenesis. Additional studies would need to be
conducted to determine if ageing the CD82KO mice would also contribute to
disease burden. It has been shown that CD82 expression is enriched in HSPCs
and expression gradually decreases towards more differentiated hematopoietic
populations (Burchert et al., 1999; Hur et al., 2016). Therefore, determining if
CD82 expression decreases overtime in the HSPC population in aging mice
could be important to better understand the mechanism of HSPC aging.
HSPC homing is a multi-step process that is mediated by a combination of
molecules such as signaling and adhesion molecules. The defect we detected in
CD82KO HSPCs was due in part to hyper-activation of Rac1, where homing was
recovered with the use of Rac1 inhibitors. Future studies could determine if other
Rho GTPases such as Cdc42 or RhoA levels are also differentially expressed in
CD82KO HSPCs. Other studies have shown that RhoA expression contributes to
weak interactions of cells (Lawson and Burridge, 2014), which could potentially
contribute to the decrease in CD82KO HSPCs we detect in the bone marrow.
Additionally, Cdc42 has also been shown to be an important mediator of HSPC
quiescence, homing and retention (Liu et al., 2011b; Williams et al., 2008; Yang
et al., 2001; Yang and Zheng, 2007). Many studies have shown that the loss of
Cdc42 contributes to increased stem cell activation, decreased LT-HSCs within
the bone marrow, decreased homing, increased mobilization and myeloid
skewing (Yang and Zheng, 2007). These defects are also consistent with what
we observed with CD82KO HSPCs.
Under basal conditions, HSPCs are found within the peripheral blood at
very low amounts but can be increased with mobilizing drugs. In addition to
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CXCR4, the S1PR is important for HSPC mobilization. We determined that CD82
regulates HSPC mobilization through the modulation of surface S1PR1
expression. CD82KO HSPCs have increased S1PR1 expression, which we
determined was due to decreased receptor internalization. However, it is still
unclear if CD82 directly or indirectly contributes to S1PR1 internalization. Our
data indicate that under basal levels CD82KO HSPCs have decreased S1PR1
internalization, however, upon treatment with S1P ligand, S1PR1 internalization is
enhanced when compared to WT HSPCs. One explanation for increased S1PR1
internalization upon S1P treatment could be due to increased expression of
surface S1PR1. Increased S1PR1 internalization in CD82KO HSPC is consistent
with increased pERK and pAKT signaling upon S1P treatment. It is known that
S1PR1 signaling still occurs on early endosomes upon ligand binding and then is
recycled back to the plasma membrane (Mullershausen et al., 2009; Reeves et
al., 2016; Thangada et al., 2010). Therefore, the increase in CD82KO HSPC
S1PR1 signaling could be due to increased receptor recycling. In addition, the
results we found are with S1P treatment, which is not specific to S1PR1,
therefore treatment with SEW2871, another S1PR1 agonist would be critical to
tease out the mechanism for downstream mediated signaling of this receptor.
In conclusion, studies described in this dissertation have provided
evidence that tetraspanins are important regulators of HSPC function. More
importantly we have identified additional roles for CD82 in the regulation of
HSPC quiescence, homing, engraftment and mobilization. The current limitations
of bone marrow transplants are 1) limited numbers of transplanted stem cells
engraft into the bone marrow and 2) limited numbers of stem cells acquired at the
time of collection. Our studies have provided evidence that the modulation of
CD82 could be used in the clinic to address these two main limitations. For
example, we provided evidence that CD82 can be exploited to promote HSPC
homing and improve bone marrow transplant. Additionally, CD82 may be a
therapeutic target to enhance HSC mobilization into the blood to increase HSC
numbers acquired for bone marrow transplants. My collective dissertation
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presents evidence of the critical role for CD82 in the regulation of HSPC fitness
and bone marrow retention.
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Appendices
Appendix A: Abbreviations used
5-FU- fluorouracil
ANG-1– angiopoietin 1
AML – acute myeloid leukemia
AKT– protein kinase B
BOYJ– B6.SJL-Ptprca Pepcb/BoyJ mice
BMP – bone morphogenic protein
BrdU– bromodeoxyuridine
CCG – Cys-Cys-Gly amino acid motif within large tetraspanin loop
CD82KO—Knock out of CD82
CFU – colony forming unit
CLL – chronic lymphocytic leukemia
CLP– common lymphoid progenitor
CML– chronic myeloid leukemia
CMP – common myeloid progenitor
CXCL12 – C-X-C motif ligand 12, also known as SDF-1
CXCR4– C-X-C chemokine receptor 4
DARC – Duffy antigen/chemokine receptor
EC1 – small extracellular loop of tetraspanins
EC2 – large extracellular loop of tetraspanins
ECM – extracellular matrix
EGFR – epidermal growth factor receptor
ELISA- enzyme-linked immunosorbent assay
ERK – extracellular signal-regulated kinases
E-selectin – Endothelial selectin
FACS– fluorescence-activated cell sorting
FN– fibronectin
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FLT-3 – FMS-like tyrosine kinase 3
FOXO1A– forkhead box protein O1a
GAP–GTPases-activating protein
G-CSF – granulocyte-colony stimulating factor
GM-CSF – granulocyte-macrophage colony-stimulating factor
GDP–guanine diphosphate
GEF–Guanine nucleotide exchage factor
GLISA–small GTPase activation assay
GMP–granulocyte-macrophage progenitor
GPCR – G-protein-coupled receptor
GTP – guanosine triphosphate
GVHD – graft-versus-host disease
GVL–graft-versus-leukemia
GVT–graft-versus-tumor
HIV–human immunodeficiency virus
HLA – human leukocyte antigen
HSPC – hematopoietic stem/progenitor cell
HSC – hematopoietic stem cell
HSCT– hematopoietic stem cell transplantation
IACUC– institutional animal care and use committee
ICAM-1 – intracellular adhesion molecule-1
IDB– ingenol 3,20 dibenzoate
JAK–janus kinase
Ki-67–nuclear antigen for proliferation
KO–knock out
Lin (-) – lineage negative
LM–laminin
LT-HSC – long-term hematopoietic stem cell
LTMR–long-term multi-lineage repopulating
L-selectin–leukocyte selectin
LSK–Lin-Sca+ckit+, HSPC population
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MAPK – mitogen-activated protein kinase
MEP–megakaryocyte erythrocyte progenitor
MFI–mean fluorescence intensity
MLL – mixed-lineage leukemia
MMP-9–matrix metalloproteinase-9
MPL – myeloproliferative leukemia
MPP – multipotent progenitor cell
MSC – mesenchymal stem cell
N-CAD- N-cadherin
N-ICD – Notch intracellular receptor domain
NSG – NOD scid gamma
PAK–p21 activating kinase
PBSCs–peripheral blood stem cells
PBX1–pre B cell actute lymphoblastic leukemia
PI3K – phosphoinositide-3-kinase
PKC – protein kinase C
PMA – phorbol 12-myristate 13-acetate
P-selectin–platelet selectin
RAC1–ras-related C3 botulinum toxin substrate 1
RAC2– ras-related C3 botulinum toxin substrate 2
SCF – stem cell factor
SDF-1 – stromal cell-derived factor-1, also known as CXCL12
SFEM–serum free expansion medium
S1P–sphingosine 1-phosphate
S1PR–sphingosine 1-phosphate receptor
SNO – N-cadherin+CD45SPHK-1– shingosine phosphate 1 kinase 1
STAT5 – signal transducer and activator of transcription 5
ST-HSC –short term hematopoietic stem cells
Tcf/Lef – T-cell factor/lymphoid enhancer factor
TEM – tetraspanin enriched microdomain
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TIE2–angiopoietin receptor
TIMP1–tissue inhibitor of metalloproteinase
TGF – transforming growth factor
TNF–tumor necrosis factor
TPO – thrombopoietin
VCAM-1 – vascular cell adhesion molecule 1
WT–wild type
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Appendix B: Supplemental Data
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Figure S1: Serial Transplantation of WT and CD82KO HSPCs. (A)
Experimental scheme for a primary engraftment experiment. (B) Experimental
scheme for a serial transplantation experiment. (C-F) The percentage of donor
cell repopulation of peripheral blood collected monthly from tail bleeds for primary
to quaternary engraftment studies. Error bars, SEM; n= 5-15 mice per strain,
Student’s t-test (**p<0.01 and ****p<0.0001).
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Figure S2: WT and CD82KO Serial Transplantation immune cells (A-D) Flow
cytometry analysis of the percentage of donor immune cells (B cells (B220), T
cells (CD3) and myeloid cells (Gr1/Mac1)) from donor population in S1. Error
bars, SEM; n= 5-15 mice per strain (*p<0.05, **p<0.01, ***p<0.001 and
****p<0.0001).
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Figure S3: CD82KO mice have increased aortic lipid content. WT and
CD82KO aortas stained with Oil Red O to assess lipid content. Unpaired t-test,
(*p<0.05).
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